EP1641765A1 - Produits aryl-heteroaromatiques, compositions les contenant et utilisation - Google Patents
Produits aryl-heteroaromatiques, compositions les contenant et utilisationInfo
- Publication number
- EP1641765A1 EP1641765A1 EP04767247A EP04767247A EP1641765A1 EP 1641765 A1 EP1641765 A1 EP 1641765A1 EP 04767247 A EP04767247 A EP 04767247A EP 04767247 A EP04767247 A EP 04767247A EP 1641765 A1 EP1641765 A1 EP 1641765A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- phenyl
- piperazin
- methanone
- pyrrol
- imidazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title abstract description 179
- 150000001875 compounds Chemical class 0.000 claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 4
- 229940079593 drug Drugs 0.000 claims abstract description 3
- -1 5-methyl-3-phenyl-isoxazol-4-yl Chemical group 0.000 claims description 83
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 17
- 125000001072 heteroaryl group Chemical group 0.000 claims description 17
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 16
- 150000002367 halogens Chemical class 0.000 claims description 13
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzenecarbonitrile Natural products N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- OAWKLWMJWIMLCV-UHFFFAOYSA-N [4-(3,5-dimethoxyphenyl)piperazin-1-yl]-(4-phenyl-1h-pyrrol-3-yl)methanone Chemical compound COC1=CC(OC)=CC(N2CCN(CC2)C(=O)C=2C(=CNC=2)C=2C=CC=CC=2)=C1 OAWKLWMJWIMLCV-UHFFFAOYSA-N 0.000 claims description 10
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 9
- 125000003118 aryl group Chemical group 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- NSWNHLDZPLNTDC-UHFFFAOYSA-N [4-(3,5-dimethoxyphenyl)piperazin-1-yl]-(2-phenyl-1h-pyrrol-3-yl)methanone Chemical compound COC1=CC(OC)=CC(N2CCN(CC2)C(=O)C2=C(NC=C2)C=2C=CC=CC=2)=C1 NSWNHLDZPLNTDC-UHFFFAOYSA-N 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 230000035755 proliferation Effects 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 5
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 claims description 5
- AIWHFPNNPDGVST-UHFFFAOYSA-N 3-[4-(4-phenyl-1h-pyrrole-3-carbonyl)piperazin-1-yl]benzamide Chemical compound NC(=O)C1=CC=CC(N2CCN(CC2)C(=O)C=2C(=CNC=2)C=2C=CC=CC=2)=C1 AIWHFPNNPDGVST-UHFFFAOYSA-N 0.000 claims description 5
- JRIMABXHSLDPOY-UHFFFAOYSA-N 3-[4-(4-phenyl-1h-pyrrole-3-carbonyl)piperazin-1-yl]benzonitrile Chemical compound C=1NC=C(C=2C=CC=CC=2)C=1C(=O)N(CC1)CCN1C1=CC=CC(C#N)=C1 JRIMABXHSLDPOY-UHFFFAOYSA-N 0.000 claims description 5
- DSABEFXPCZJARP-UHFFFAOYSA-N [4-(3-chlorophenyl)piperazin-1-yl]-(4-phenyl-1h-pyrrol-3-yl)methanone Chemical compound ClC1=CC=CC(N2CCN(CC2)C(=O)C=2C(=CNC=2)C=2C=CC=CC=2)=C1 DSABEFXPCZJARP-UHFFFAOYSA-N 0.000 claims description 5
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 5
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 5
- 125000003107 substituted aryl group Chemical group 0.000 claims description 5
- RYUWWELMYPXZKJ-UHFFFAOYSA-N 3-[4-(2-phenyl-1h-pyrrole-3-carbonyl)piperazin-1-yl]benzonitrile Chemical compound C1=CNC(C=2C=CC=CC=2)=C1C(=O)N(CC1)CCN1C1=CC=CC(C#N)=C1 RYUWWELMYPXZKJ-UHFFFAOYSA-N 0.000 claims description 4
- WQLGNVRHIMLWDT-UHFFFAOYSA-N [4-(3,5-dimethoxyphenyl)piperazin-1-yl]-(2-methyl-4-phenyl-1,3-thiazol-5-yl)methanone Chemical compound COC1=CC(OC)=CC(N2CCN(CC2)C(=O)C2=C(N=C(C)S2)C=2C=CC=CC=2)=C1 WQLGNVRHIMLWDT-UHFFFAOYSA-N 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims description 4
- IMWLLSZOLWWMTG-UHFFFAOYSA-N (4-phenyl-1h-imidazol-5-yl)-(4-pyridin-3-ylpiperazin-1-yl)methanone Chemical compound N1C=NC(C=2C=CC=CC=2)=C1C(=O)N(CC1)CCN1C1=CC=CN=C1 IMWLLSZOLWWMTG-UHFFFAOYSA-N 0.000 claims description 3
- SKYGBVSXNUUDNF-UHFFFAOYSA-N 2-[2-[4-(3-carbamoylphenyl)piperazine-1-carbonyl]-3-phenylpyrrol-1-yl]acetic acid Chemical compound NC(=O)C1=CC=CC(N2CCN(CC2)C(=O)C=2N(C=CC=2C=2C=CC=CC=2)CC(O)=O)=C1 SKYGBVSXNUUDNF-UHFFFAOYSA-N 0.000 claims description 3
- BZNNBSRLVYNHAS-UHFFFAOYSA-N 2-[3-[4-(3,5-dimethoxyphenyl)piperazine-1-carbonyl]-4-phenylpyrrol-1-yl]acetic acid Chemical compound COC1=CC(OC)=CC(N2CCN(CC2)C(=O)C=2C(=CN(CC(O)=O)C=2)C=2C=CC=CC=2)=C1 BZNNBSRLVYNHAS-UHFFFAOYSA-N 0.000 claims description 3
- FWCBBSTVUAASDV-UHFFFAOYSA-N 3-[4-(2-amino-4-phenyl-1,3-thiazole-5-carbonyl)piperazin-1-yl]benzamide Chemical compound NC(=O)C1=CC=CC(N2CCN(CC2)C(=O)C2=C(N=C(N)S2)C=2C=CC=CC=2)=C1 FWCBBSTVUAASDV-UHFFFAOYSA-N 0.000 claims description 3
- ZNHCXYGJSDERCQ-UHFFFAOYSA-N 3-[4-(2-amino-4-phenyl-1,3-thiazole-5-carbonyl)piperazin-1-yl]benzonitrile Chemical compound S1C(N)=NC(C=2C=CC=CC=2)=C1C(=O)N(CC1)CCN1C1=CC=CC(C#N)=C1 ZNHCXYGJSDERCQ-UHFFFAOYSA-N 0.000 claims description 3
- GALSDOHLAKFIBA-UHFFFAOYSA-N 3-[4-(2-methylsulfanyl-4-phenyl-1h-imidazole-5-carbonyl)piperazin-1-yl]benzonitrile Chemical compound N1C(SC)=NC(C=2C=CC=CC=2)=C1C(=O)N(CC1)CCN1C1=CC=CC(C#N)=C1 GALSDOHLAKFIBA-UHFFFAOYSA-N 0.000 claims description 3
- NEHPYIZYRXFJNI-UHFFFAOYSA-N 3-[4-(2-methylsulfonyl-5-phenyl-1,4-dihydroimidazole-5-carbonyl)piperazin-1-yl]benzonitrile Chemical compound C1NC(S(=O)(=O)C)=NC1(C=1C=CC=CC=1)C(=O)N1CCN(C=2C=C(C=CC=2)C#N)CC1 NEHPYIZYRXFJNI-UHFFFAOYSA-N 0.000 claims description 3
- LUSHKMRYBKWJGE-UHFFFAOYSA-N 3-[4-(2-oxo-5-phenyl-1,3-dihydroimidazole-4-carbonyl)piperazin-1-yl]benzonitrile Chemical compound N1C(O)=NC(C=2C=CC=CC=2)=C1C(=O)N(CC1)CCN1C1=CC=CC(C#N)=C1 LUSHKMRYBKWJGE-UHFFFAOYSA-N 0.000 claims description 3
- YEHAFSPUXRGMOF-UHFFFAOYSA-N 3-[4-(3-phenylimidazole-4-carbonyl)piperazin-1-yl]benzonitrile Chemical compound C=1N=CN(C=2C=CC=CC=2)C=1C(=O)N(CC1)CCN1C1=CC=CC(C#N)=C1 YEHAFSPUXRGMOF-UHFFFAOYSA-N 0.000 claims description 3
- IISFNCJURYTOGV-UHFFFAOYSA-N 3-[4-(4-phenyl-1h-imidazole-5-carbonyl)piperazin-1-yl]benzonitrile Chemical compound N1C=NC(C=2C=CC=CC=2)=C1C(=O)N(CC1)CCN1C1=CC=CC(C#N)=C1 IISFNCJURYTOGV-UHFFFAOYSA-N 0.000 claims description 3
- ZTTWJHFZPZPYHD-UHFFFAOYSA-N 3-[4-(5-phenyl-2-sulfanylidene-1,3-dihydroimidazole-4-carbonyl)piperazin-1-yl]benzamide Chemical compound NC(=O)C1=CC=CC(N2CCN(CC2)C(=O)C2=C(N=C(S)N2)C=2C=CC=CC=2)=C1 ZTTWJHFZPZPYHD-UHFFFAOYSA-N 0.000 claims description 3
- HRJGULOIKVEEDQ-UHFFFAOYSA-N 3-[4-(5-phenyl-2-sulfanylidene-1,3-dihydroimidazole-4-carbonyl)piperazin-1-yl]benzonitrile Chemical compound N1C(S)=NC(C=2C=CC=CC=2)=C1C(=O)N(CC1)CCN1C1=CC=CC(C#N)=C1 HRJGULOIKVEEDQ-UHFFFAOYSA-N 0.000 claims description 3
- QSBGOQPVAJOLDM-UHFFFAOYSA-N 3-[4-[1-(1-hydroxyethyl)-2-phenylpyrrole-3-carbonyl]piperazin-1-yl]benzamide Chemical compound C=1C=CC=CC=1C=1N(C(O)C)C=CC=1C(=O)N(CC1)CCN1C1=CC=CC(C(N)=O)=C1 QSBGOQPVAJOLDM-UHFFFAOYSA-N 0.000 claims description 3
- CHXKZVOYQIWWLU-UHFFFAOYSA-N 3-[4-[1-(1-hydroxyethyl)-2-phenylpyrrole-3-carbonyl]piperazin-1-yl]benzonitrile Chemical compound C=1C=CC=CC=1C=1N(C(O)C)C=CC=1C(=O)N(CC1)CCN1C1=CC=CC(C#N)=C1 CHXKZVOYQIWWLU-UHFFFAOYSA-N 0.000 claims description 3
- STZQWSSMWQRLDC-UHFFFAOYSA-N 3-[4-[1-(1-hydroxyethyl)-4-phenylpyrrole-3-carbonyl]piperazin-1-yl]benzonitrile Chemical compound C=1C=CC=CC=1C1=CN(C(O)C)C=C1C(=O)N(CC1)CCN1C1=CC=CC(C#N)=C1 STZQWSSMWQRLDC-UHFFFAOYSA-N 0.000 claims description 3
- CPBQHWOZKOBKHX-UHFFFAOYSA-N 3-[4-[1-(hydroxymethyl)-4-phenylpyrrole-3-carbonyl]piperazin-1-yl]benzonitrile Chemical compound C=1C=CC=CC=1C1=CN(CO)C=C1C(=O)N(CC1)CCN1C1=CC=CC(C#N)=C1 CPBQHWOZKOBKHX-UHFFFAOYSA-N 0.000 claims description 3
- JTIAFBAAEUDXGG-UHFFFAOYSA-N 3-[4-[2-(2-methoxyethylamino)-4-phenyl-1,3-thiazole-5-carbonyl]piperazin-1-yl]benzamide Chemical compound S1C(NCCOC)=NC(C=2C=CC=CC=2)=C1C(=O)N(CC1)CCN1C1=CC=CC(C(N)=O)=C1 JTIAFBAAEUDXGG-UHFFFAOYSA-N 0.000 claims description 3
- COVMDYQQYPZRGL-UHFFFAOYSA-N 3-[4-[4-phenyl-2-(trifluoromethyl)-1h-imidazole-5-carbonyl]piperazin-1-yl]benzonitrile Chemical compound N1C(C(F)(F)F)=NC(C=2C=CC=CC=2)=C1C(=O)N(CC1)CCN1C1=CC=CC(C#N)=C1 COVMDYQQYPZRGL-UHFFFAOYSA-N 0.000 claims description 3
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 3
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 claims description 3
- YNOAMDJRZSNZPH-UHFFFAOYSA-N 4-[3-[4-(3,5-dimethoxyphenyl)piperazine-1-carbonyl]-4-phenylpyrrol-1-yl]butanoic acid Chemical compound COC1=CC(OC)=CC(N2CCN(CC2)C(=O)C=2C(=CN(CCCC(O)=O)C=2)C=2C=CC=CC=2)=C1 YNOAMDJRZSNZPH-UHFFFAOYSA-N 0.000 claims description 3
- BNWDQWYSAQEDHZ-UHFFFAOYSA-N 4-[4-[3-(hydroxymethyl)phenyl]piperazine-1-carbonyl]-5-phenyl-1,3-dihydroimidazol-2-one Chemical compound OCC1=CC=CC(N2CCN(CC2)C(=O)C2=C(N=C(O)N2)C=2C=CC=CC=2)=C1 BNWDQWYSAQEDHZ-UHFFFAOYSA-N 0.000 claims description 3
- SCXTYHPIUZWMRP-UHFFFAOYSA-N 5-[4-(3,5-dimethoxyphenyl)piperazine-1-carbonyl]-4-phenyl-3h-1,3-thiazol-2-one Chemical compound COC1=CC(OC)=CC(N2CCN(CC2)C(=O)C2=C(N=C(O)S2)C=2C=CC=CC=2)=C1 SCXTYHPIUZWMRP-UHFFFAOYSA-N 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- AAKVKMQATUOQAK-UHFFFAOYSA-N [2-(4-chlorophenyl)furan-3-yl]-[4-(3-methoxyphenyl)piperazin-1-yl]methanone Chemical compound COC1=CC=CC(N2CCN(CC2)C(=O)C2=C(OC=C2)C=2C=CC(Cl)=CC=2)=C1 AAKVKMQATUOQAK-UHFFFAOYSA-N 0.000 claims description 3
- QQKQEAWOHYCALI-UHFFFAOYSA-N [4-(2-hydroxy-3,5-dimethoxyphenyl)piperazin-1-yl]-(2-methylsulfinyl-4-phenyl-1h-imidazol-5-yl)methanone Chemical compound COC1=CC(OC)=C(O)C(N2CCN(CC2)C(=O)C2=C(NC(=N2)S(C)=O)C=2C=CC=CC=2)=C1 QQKQEAWOHYCALI-UHFFFAOYSA-N 0.000 claims description 3
- LZEKYSVYSVNYLZ-UHFFFAOYSA-N [4-(3,5-dimethoxyphenyl)piperazin-1-yl]-(2-methyl-4-phenyl-1h-imidazol-5-yl)methanone Chemical compound COC1=CC(OC)=CC(N2CCN(CC2)C(=O)C2=C(N=C(C)N2)C=2C=CC=CC=2)=C1 LZEKYSVYSVNYLZ-UHFFFAOYSA-N 0.000 claims description 3
- IMBCURQZYXRXET-UHFFFAOYSA-N [4-(3,5-dimethoxyphenyl)piperazin-1-yl]-(2-methylsulfanyl-4-phenyl-1h-imidazol-5-yl)methanone Chemical compound COC1=CC(OC)=CC(N2CCN(CC2)C(=O)C2=C(NC(SC)=N2)C=2C=CC=CC=2)=C1 IMBCURQZYXRXET-UHFFFAOYSA-N 0.000 claims description 3
- RBJKVCUOOLRIJY-UHFFFAOYSA-N [4-(3,5-dimethoxyphenyl)piperazin-1-yl]-(4-phenyl-1,3-thiazol-5-yl)methanone Chemical compound COC1=CC(OC)=CC(N2CCN(CC2)C(=O)C2=C(N=CS2)C=2C=CC=CC=2)=C1 RBJKVCUOOLRIJY-UHFFFAOYSA-N 0.000 claims description 3
- UPPIQJMQCOKLFP-UHFFFAOYSA-N [4-(3,5-dimethoxyphenyl)piperazin-1-yl]-(4-phenyl-1h-imidazol-5-yl)methanone Chemical compound COC1=CC(OC)=CC(N2CCN(CC2)C(=O)C2=C(N=CN2)C=2C=CC=CC=2)=C1 UPPIQJMQCOKLFP-UHFFFAOYSA-N 0.000 claims description 3
- VFEOPGDDGZTXOA-UHFFFAOYSA-N [4-(3,5-dimethoxyphenyl)piperazin-1-yl]-[1-(hydroxymethyl)-4-phenylpyrrol-3-yl]methanone Chemical compound COC1=CC(OC)=CC(N2CCN(CC2)C(=O)C=2C(=CN(CO)C=2)C=2C=CC=CC=2)=C1 VFEOPGDDGZTXOA-UHFFFAOYSA-N 0.000 claims description 3
- YRFHMXBFNPQYAP-UHFFFAOYSA-N [4-(3,5-dimethoxyphenyl)piperazin-1-yl]-[2-(2-methoxyethylamino)-4-phenyl-1,3-thiazol-5-yl]methanone Chemical compound S1C(NCCOC)=NC(C=2C=CC=CC=2)=C1C(=O)N(CC1)CCN1C1=CC(OC)=CC(OC)=C1 YRFHMXBFNPQYAP-UHFFFAOYSA-N 0.000 claims description 3
- BRIZJOCBJNSECZ-UHFFFAOYSA-N [4-(3,5-dimethoxyphenyl)piperazin-1-yl]-[4-phenyl-1-(1,3-thiazol-4-ylmethyl)pyrrol-3-yl]methanone Chemical compound COC1=CC(OC)=CC(N2CCN(CC2)C(=O)C=2C(=CN(CC=3N=CSC=3)C=2)C=2C=CC=CC=2)=C1 BRIZJOCBJNSECZ-UHFFFAOYSA-N 0.000 claims description 3
- DQMKNHROPZQKGW-UHFFFAOYSA-N [4-(3,5-dimethoxyphenyl)piperazin-1-yl]-[4-phenyl-1-(pyridin-3-ylmethyl)pyrrol-3-yl]methanone Chemical compound COC1=CC(OC)=CC(N2CCN(CC2)C(=O)C=2C(=CN(CC=3C=NC=CC=3)C=2)C=2C=CC=CC=2)=C1 DQMKNHROPZQKGW-UHFFFAOYSA-N 0.000 claims description 3
- LRBHFVPAJZCNQL-UHFFFAOYSA-N [4-(3,5-dimethylphenyl)piperazin-1-yl]-[2-(2-methoxyethylamino)-4-phenyl-1,3-thiazol-5-yl]methanone Chemical compound S1C(NCCOC)=NC(C=2C=CC=CC=2)=C1C(=O)N(CC1)CCN1C1=CC(C)=CC(C)=C1 LRBHFVPAJZCNQL-UHFFFAOYSA-N 0.000 claims description 3
- XEGWLHUDVLKYJU-UHFFFAOYSA-N [4-(3-chlorophenyl)piperazin-1-yl]-(2-phenyl-1h-pyrrol-3-yl)methanone Chemical compound ClC1=CC=CC(N2CCN(CC2)C(=O)C2=C(NC=C2)C=2C=CC=CC=2)=C1 XEGWLHUDVLKYJU-UHFFFAOYSA-N 0.000 claims description 3
- MXCRMZHVUFLCCD-UHFFFAOYSA-N [4-(3-chlorophenyl)piperazin-1-yl]-(3-phenyl-1h-pyrrol-2-yl)methanone Chemical compound ClC1=CC=CC(N2CCN(CC2)C(=O)C2=C(C=CN2)C=2C=CC=CC=2)=C1 MXCRMZHVUFLCCD-UHFFFAOYSA-N 0.000 claims description 3
- WELRZMGYQBXTOR-UHFFFAOYSA-N [4-(3-chlorophenyl)piperazin-1-yl]-(3-phenylthiophen-2-yl)methanone Chemical compound ClC1=CC=CC(N2CCN(CC2)C(=O)C2=C(C=CS2)C=2C=CC=CC=2)=C1 WELRZMGYQBXTOR-UHFFFAOYSA-N 0.000 claims description 3
- GYDZOYOOITWUFO-UHFFFAOYSA-N [4-(3-chlorophenyl)piperazin-1-yl]-(5-phenyl-2-sulfanylidene-1,3-dihydroimidazol-4-yl)methanone Chemical compound C=1C=CC=CC=1C=1NC(S)=NC=1C(=O)N(CC1)CCN1C1=CC=CC(Cl)=C1 GYDZOYOOITWUFO-UHFFFAOYSA-N 0.000 claims description 3
- SGMKXOIIRHQVMG-UHFFFAOYSA-N [4-(3-methoxyphenyl)piperazin-1-yl]-(4-phenyl-1h-imidazol-5-yl)methanone Chemical compound COC1=CC=CC(N2CCN(CC2)C(=O)C2=C(N=CN2)C=2C=CC=CC=2)=C1 SGMKXOIIRHQVMG-UHFFFAOYSA-N 0.000 claims description 3
- WQCNPOUJOFYEEP-UHFFFAOYSA-N [4-[3-(difluoromethoxy)phenyl]piperazin-1-yl]-(4-phenyl-1h-imidazol-5-yl)methanone Chemical compound FC(F)OC1=CC=CC(N2CCN(CC2)C(=O)C2=C(NC=N2)C=2C=CC=CC=2)=C1 WQCNPOUJOFYEEP-UHFFFAOYSA-N 0.000 claims description 3
- WKDUJKVNQLAUAQ-UHFFFAOYSA-N [4-[3-(hydroxymethyl)phenyl]piperazin-1-yl]-(2-phenyl-1h-pyrrol-3-yl)methanone Chemical compound OCC1=CC=CC(N2CCN(CC2)C(=O)C2=C(NC=C2)C=2C=CC=CC=2)=C1 WKDUJKVNQLAUAQ-UHFFFAOYSA-N 0.000 claims description 3
- SVWOOCWFNNIZDA-UHFFFAOYSA-N [4-[3-(hydroxymethyl)phenyl]piperazin-1-yl]-(4-phenyl-1h-imidazol-5-yl)methanone Chemical compound OCC1=CC=CC(N2CCN(CC2)C(=O)C2=C(N=CN2)C=2C=CC=CC=2)=C1 SVWOOCWFNNIZDA-UHFFFAOYSA-N 0.000 claims description 3
- IPPYKVVIHANXTQ-UHFFFAOYSA-N [4-[3-(hydroxymethyl)phenyl]piperazin-1-yl]-[4-phenyl-2-(trifluoromethyl)-1h-imidazol-5-yl]methanone Chemical compound OCC1=CC=CC(N2CCN(CC2)C(=O)C2=C(N=C(N2)C(F)(F)F)C=2C=CC=CC=2)=C1 IPPYKVVIHANXTQ-UHFFFAOYSA-N 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 230000001575 pathological effect Effects 0.000 claims description 3
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 3
- 210000004881 tumor cell Anatomy 0.000 claims description 3
- JSQFVFVKZGVANQ-UHFFFAOYSA-N (2-amino-4-phenyl-1,3-thiazol-5-yl)-[4-[3-(hydroxymethyl)phenyl]piperazin-1-yl]methanone Chemical compound S1C(N)=NC(C=2C=CC=CC=2)=C1C(=O)N(CC1)CCN1C1=CC=CC(CO)=C1 JSQFVFVKZGVANQ-UHFFFAOYSA-N 0.000 claims description 2
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims description 2
- AIDJMQKZDVULAF-UHFFFAOYSA-N 1-[3-[4-(3,5-dimethoxyphenyl)piperazine-1-carbonyl]-2-phenylpyrrol-1-yl]ethanone Chemical compound COC1=CC(OC)=CC(N2CCN(CC2)C(=O)C2=C(N(C(C)=O)C=C2)C=2C=CC=CC=2)=C1 AIDJMQKZDVULAF-UHFFFAOYSA-N 0.000 claims description 2
- XFIVHJKOEPNRCT-UHFFFAOYSA-N 1-[3-[4-(3,5-dimethoxyphenyl)piperazine-1-carbonyl]-4-phenylpyrrol-1-yl]ethanone Chemical compound COC1=CC(OC)=CC(N2CCN(CC2)C(=O)C=2C(=CN(C=2)C(C)=O)C=2C=CC=CC=2)=C1 XFIVHJKOEPNRCT-UHFFFAOYSA-N 0.000 claims description 2
- JKPTUXAJNUGFNI-UHFFFAOYSA-N 3-[3-[4-(3-chlorophenyl)piperazine-1-carbonyl]-4-phenylpyrrol-1-yl]propanoic acid Chemical compound C=1C=CC=CC=1C1=CN(CCC(=O)O)C=C1C(=O)N(CC1)CCN1C1=CC=CC(Cl)=C1 JKPTUXAJNUGFNI-UHFFFAOYSA-N 0.000 claims description 2
- DRLKOALDPMGLJV-UHFFFAOYSA-N 3-[4-(1-methyl-2-phenylpyrrole-3-carbonyl)piperazin-1-yl]benzamide Chemical compound C=1C=CC=CC=1C=1N(C)C=CC=1C(=O)N(CC1)CCN1C1=CC=CC(C(N)=O)=C1 DRLKOALDPMGLJV-UHFFFAOYSA-N 0.000 claims description 2
- MGNLQALRHMQGRS-UHFFFAOYSA-N 3-[4-(1-methyl-4-phenylpyrrole-3-carbonyl)piperazin-1-yl]benzamide Chemical compound C=1C=CC=CC=1C1=CN(C)C=C1C(=O)N(CC1)CCN1C1=CC=CC(C(N)=O)=C1 MGNLQALRHMQGRS-UHFFFAOYSA-N 0.000 claims description 2
- CTHNOHWYNHLGMV-UHFFFAOYSA-N 3-[4-(2-methyl-4-phenyl-1h-imidazole-5-carbonyl)piperazin-1-yl]benzonitrile Chemical compound C=1C=CC=CC=1C=1NC(C)=NC=1C(=O)N(CC1)CCN1C1=CC=CC(C#N)=C1 CTHNOHWYNHLGMV-UHFFFAOYSA-N 0.000 claims description 2
- ANVWTMJBEHMJDK-UHFFFAOYSA-N 3-[4-(2-methylsulfanyl-4-phenyl-1h-imidazole-5-carbonyl)piperazin-1-yl]benzamide Chemical compound N1C(SC)=NC(C=2C=CC=CC=2)=C1C(=O)N(CC1)CCN1C1=CC=CC(C(N)=O)=C1 ANVWTMJBEHMJDK-UHFFFAOYSA-N 0.000 claims description 2
- OSMVJIRBVRPVLQ-UHFFFAOYSA-N 3-[4-(3-phenyl-1h-pyrrole-2-carbonyl)piperazin-1-yl]benzamide Chemical compound NC(=O)C1=CC=CC(N2CCN(CC2)C(=O)C2=C(C=CN2)C=2C=CC=CC=2)=C1 OSMVJIRBVRPVLQ-UHFFFAOYSA-N 0.000 claims description 2
- PUUUQTODUUKDOB-UHFFFAOYSA-N 3-[4-[2-(2-methoxyethylamino)-4-phenyl-1,3-thiazole-5-carbonyl]piperazin-1-yl]benzonitrile Chemical compound S1C(NCCOC)=NC(C=2C=CC=CC=2)=C1C(=O)N(CC1)CCN1C1=CC=CC(C#N)=C1 PUUUQTODUUKDOB-UHFFFAOYSA-N 0.000 claims description 2
- KNFJXXWJPOVNAZ-UHFFFAOYSA-N 3-[4-[4-phenyl-2-(trifluoromethyl)-1h-imidazole-5-carbonyl]piperazin-1-yl]benzamide Chemical compound NC(=O)C1=CC=CC(N2CCN(CC2)C(=O)C2=C(N=C(N2)C(F)(F)F)C=2C=CC=CC=2)=C1 KNFJXXWJPOVNAZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 2
- XOULNWKRRGEGHW-UHFFFAOYSA-N 4-[4-(3,5-dimethoxyphenyl)piperazine-1-carbonyl]-5-phenyl-1,3-dihydroimidazol-2-one Chemical compound COC1=CC(OC)=CC(N2CCN(CC2)C(=O)C2=C(NC(O)=N2)C=2C=CC=CC=2)=C1 XOULNWKRRGEGHW-UHFFFAOYSA-N 0.000 claims description 2
- XZRAZBBODBSFKM-UHFFFAOYSA-N [1-(1-hydroxyethyl)-5-phenylpyrrol-2-yl]-[4-[3-(hydroxymethyl)phenyl]piperazin-1-yl]methanone Chemical compound CC(O)N1C(C(=O)N2CCN(CC2)C=2C=C(CO)C=CC=2)=CC=C1C1=CC=CC=C1 XZRAZBBODBSFKM-UHFFFAOYSA-N 0.000 claims description 2
- RFGDCADBISBUTA-UHFFFAOYSA-N [3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]-(4-pyridin-2-ylpiperazin-1-yl)methanone Chemical compound CC=1ON=C(C=2C(=CC=CC=2Cl)Cl)C=1C(=O)N(CC1)CCN1C1=CC=CC=N1 RFGDCADBISBUTA-UHFFFAOYSA-N 0.000 claims description 2
- QPTBXDYWAWRRBB-UHFFFAOYSA-N [3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]-[4-(2,3-dimethylphenyl)piperazin-1-yl]methanone Chemical compound CC=1ON=C(C=2C(=CC=CC=2Cl)Cl)C=1C(=O)N(CC1)CCN1C1=CC=CC(C)=C1C QPTBXDYWAWRRBB-UHFFFAOYSA-N 0.000 claims description 2
- NUZHFCHDSLXWMB-UHFFFAOYSA-N [3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]-[4-(4-fluorophenyl)piperazin-1-yl]methanone Chemical compound CC=1ON=C(C=2C(=CC=CC=2Cl)Cl)C=1C(=O)N(CC1)CCN1C1=CC=C(F)C=C1 NUZHFCHDSLXWMB-UHFFFAOYSA-N 0.000 claims description 2
- FQQQIDMUZUMOGS-UHFFFAOYSA-N [3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]-[4-(2-methoxyphenyl)piperazin-1-yl]methanone Chemical compound COC1=CC=CC=C1N1CCN(C(=O)C=2C(=NOC=2C)C=2C(=CC=CC=2F)Cl)CC1 FQQQIDMUZUMOGS-UHFFFAOYSA-N 0.000 claims description 2
- WVUKBGUNJPPZKT-UHFFFAOYSA-N [3-(2-chlorophenyl)-5-methyl-1,2-oxazol-4-yl]-[4-(2-methoxyphenyl)piperazin-1-yl]methanone Chemical compound COC1=CC=CC=C1N1CCN(C(=O)C=2C(=NOC=2C)C=2C(=CC=CC=2)Cl)CC1 WVUKBGUNJPPZKT-UHFFFAOYSA-N 0.000 claims description 2
- VZPGZECGVVSLET-UHFFFAOYSA-N [3-(2-chlorophenyl)-5-methyl-1,2-oxazol-4-yl]-[4-(3-chlorophenyl)piperazin-1-yl]methanone Chemical compound CC=1ON=C(C=2C(=CC=CC=2)Cl)C=1C(=O)N(CC1)CCN1C1=CC=CC(Cl)=C1 VZPGZECGVVSLET-UHFFFAOYSA-N 0.000 claims description 2
- JHUVHAANGXSBSY-UHFFFAOYSA-N [3-(2-chlorophenyl)-5-methyl-1,2-oxazol-4-yl]-[4-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]methanone Chemical compound CC=1ON=C(C=2C(=CC=CC=2)Cl)C=1C(=O)N(CC1)CCN1C1=NC=C(C(F)(F)F)C=C1Cl JHUVHAANGXSBSY-UHFFFAOYSA-N 0.000 claims description 2
- HHZMWKNOCCEMIJ-UHFFFAOYSA-N [4-(2-chlorophenyl)-5-methyl-1,2-oxazol-3-yl]-[4-(2-fluorophenyl)piperazin-1-yl]methanone Chemical compound C=1C=CC=C(Cl)C=1C1=C(C)ON=C1C(=O)N(CC1)CCN1C1=CC=CC=C1F HHZMWKNOCCEMIJ-UHFFFAOYSA-N 0.000 claims description 2
- OHIQYDFDYIMGRD-UHFFFAOYSA-N [4-(2-chlorophenyl)-5-methyl-1,2-oxazol-3-yl]-[4-(4-fluorophenyl)piperazin-1-yl]methanone Chemical compound C=1C=CC=C(Cl)C=1C1=C(C)ON=C1C(=O)N(CC1)CCN1C1=CC=C(F)C=C1 OHIQYDFDYIMGRD-UHFFFAOYSA-N 0.000 claims description 2
- KDDUFNRXJZVCGN-UHFFFAOYSA-N [4-(2-fluorophenyl)piperazin-1-yl]-(4-phenylthiadiazol-5-yl)methanone Chemical compound FC1=CC=CC=C1N1CCN(C(=O)C2=C(N=NS2)C=2C=CC=CC=2)CC1 KDDUFNRXJZVCGN-UHFFFAOYSA-N 0.000 claims description 2
- GOEPFJGUMPLVOG-UHFFFAOYSA-N [4-(2-fluorophenyl)piperazin-1-yl]-(5-methyl-3-phenyl-1,2-oxazol-4-yl)methanone Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C(=O)N(CC1)CCN1C1=CC=CC=C1F GOEPFJGUMPLVOG-UHFFFAOYSA-N 0.000 claims description 2
- DCIXECPRAXUAMO-UHFFFAOYSA-N [4-(3,5-dimethoxyphenyl)piperazin-1-yl]-(1-methyl-2-methylsulfanyl-5-phenylimidazol-4-yl)methanone Chemical compound COC1=CC(OC)=CC(N2CCN(CC2)C(=O)C2=C(N(C)C(SC)=N2)C=2C=CC=CC=2)=C1 DCIXECPRAXUAMO-UHFFFAOYSA-N 0.000 claims description 2
- ZLMTYHIPIODBGR-UHFFFAOYSA-N [4-(3,5-dimethoxyphenyl)piperazin-1-yl]-(1-methyl-2-phenylpyrrol-3-yl)methanone Chemical compound COC1=CC(OC)=CC(N2CCN(CC2)C(=O)C2=C(N(C)C=C2)C=2C=CC=CC=2)=C1 ZLMTYHIPIODBGR-UHFFFAOYSA-N 0.000 claims description 2
- ONNDHHBHLXCKTE-UHFFFAOYSA-N [4-(3,5-dimethoxyphenyl)piperazin-1-yl]-(2-methylsulfonyl-4-phenyl-1h-imidazol-5-yl)methanone Chemical compound COC1=CC(OC)=CC(N2CCN(CC2)C(=O)C2=C(N=C(N2)S(C)(=O)=O)C=2C=CC=CC=2)=C1 ONNDHHBHLXCKTE-UHFFFAOYSA-N 0.000 claims description 2
- XVJBGAZNWMPLLF-UHFFFAOYSA-N [4-(3,5-dimethoxyphenyl)piperazin-1-yl]-(3-phenyl-1h-pyrrol-2-yl)methanone Chemical compound COC1=CC(OC)=CC(N2CCN(CC2)C(=O)C2=C(C=CN2)C=2C=CC=CC=2)=C1 XVJBGAZNWMPLLF-UHFFFAOYSA-N 0.000 claims description 2
- LCSQNNICYSIJIG-UHFFFAOYSA-N [4-(3,5-dimethoxyphenyl)piperazin-1-yl]-[1-(2-hydroxyethyl)-2-phenylpyrrol-3-yl]methanone Chemical compound COC1=CC(OC)=CC(N2CCN(CC2)C(=O)C2=C(N(CCO)C=C2)C=2C=CC=CC=2)=C1 LCSQNNICYSIJIG-UHFFFAOYSA-N 0.000 claims description 2
- DWBWNWJNADJNBS-UHFFFAOYSA-N [4-(3,5-dimethoxyphenyl)piperazin-1-yl]-[1-(2-hydroxyethyl)-4-phenylpyrrol-3-yl]methanone Chemical compound COC1=CC(OC)=CC(N2CCN(CC2)C(=O)C=2C(=CN(CCO)C=2)C=2C=CC=CC=2)=C1 DWBWNWJNADJNBS-UHFFFAOYSA-N 0.000 claims description 2
- XCKUDSAUYUJIDS-UHFFFAOYSA-N [4-(3,5-dimethoxyphenyl)piperazin-1-yl]-[4-phenyl-2-(trifluoromethyl)-1h-imidazol-5-yl]methanone Chemical compound COC1=CC(OC)=CC(N2CCN(CC2)C(=O)C2=C(N=C(N2)C(F)(F)F)C=2C=CC=CC=2)=C1 XCKUDSAUYUJIDS-UHFFFAOYSA-N 0.000 claims description 2
- KSGKIURWMIQOQJ-UHFFFAOYSA-N [4-(3-chlorophenyl)piperazin-1-yl]-(4-phenyl-1h-imidazol-5-yl)methanone Chemical compound ClC1=CC=CC(N2CCN(CC2)C(=O)C2=C(N=CN2)C=2C=CC=CC=2)=C1 KSGKIURWMIQOQJ-UHFFFAOYSA-N 0.000 claims description 2
- VIMQHHSIPAKERJ-UHFFFAOYSA-N [4-(3-chlorophenyl)piperazin-1-yl]-(5-phenyl-1,3-oxazol-4-yl)methanone Chemical compound ClC1=CC=CC(N2CCN(CC2)C(=O)C2=C(OC=N2)C=2C=CC=CC=2)=C1 VIMQHHSIPAKERJ-UHFFFAOYSA-N 0.000 claims description 2
- DPKCHQOPFHKJPB-UHFFFAOYSA-N [4-(3-chlorophenyl)piperazin-1-yl]-[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]methanone Chemical compound CC=1ON=C(C=2C(=CC=CC=2Cl)Cl)C=1C(=O)N(CC1)CCN1C1=CC=CC(Cl)=C1 DPKCHQOPFHKJPB-UHFFFAOYSA-N 0.000 claims description 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- BULYQULHSJTEFI-UHFFFAOYSA-N (2,5-dimethyl-4-phenylfuran-3-yl)-(4-pyridin-2-ylpiperazin-1-yl)methanone Chemical compound CC=1OC(C)=C(C=2C=CC=CC=2)C=1C(=O)N(CC1)CCN1C1=CC=CC=N1 BULYQULHSJTEFI-UHFFFAOYSA-N 0.000 claims 1
- CQAQZWBDEWVTJJ-UHFFFAOYSA-N 3-[4-(2-methyl-4-phenyl-1h-imidazole-5-carbonyl)piperazin-1-yl]benzamide Chemical compound C=1C=CC=CC=1C=1NC(C)=NC=1C(=O)N(CC1)CCN1C1=CC=CC(C(N)=O)=C1 CQAQZWBDEWVTJJ-UHFFFAOYSA-N 0.000 claims 1
- ZPPMQRCEUMZPSQ-UHFFFAOYSA-N 3-[4-(2-methylsulfonyl-5-phenyl-1,4-dihydroimidazole-5-carbonyl)piperazin-1-yl]benzamide Chemical compound C1NC(S(=O)(=O)C)=NC1(C=1C=CC=CC=1)C(=O)N1CCN(C=2C=C(C=CC=2)C(N)=O)CC1 ZPPMQRCEUMZPSQ-UHFFFAOYSA-N 0.000 claims 1
- HXDKQFRUUMYXFI-UHFFFAOYSA-N 3-[4-(2-oxo-5-phenyl-1,3-dihydroimidazole-4-carbonyl)piperazin-1-yl]benzamide Chemical compound NC(=O)C1=CC=CC(N2CCN(CC2)C(=O)C2=C(N=C(O)N2)C=2C=CC=CC=2)=C1 HXDKQFRUUMYXFI-UHFFFAOYSA-N 0.000 claims 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
- XUVYFYAJBKTBLH-UHFFFAOYSA-N [4-(3,5-dimethoxyphenyl)piperazin-1-yl]-(1-methyl-3-phenylpyrrol-2-yl)methanone Chemical compound COC1=CC(OC)=CC(N2CCN(CC2)C(=O)C=2N(C=CC=2C=2C=CC=CC=2)C)=C1 XUVYFYAJBKTBLH-UHFFFAOYSA-N 0.000 claims 1
- GFHYHAMWWWMKJT-UHFFFAOYSA-N [4-(3,5-dimethoxyphenyl)piperazin-1-yl]-(5-methyl-3-phenyl-1,2-oxazol-4-yl)methanone Chemical compound COC1=CC(OC)=CC(N2CCN(CC2)C(=O)C=2C(=NOC=2C)C=2C=CC=CC=2)=C1 GFHYHAMWWWMKJT-UHFFFAOYSA-N 0.000 claims 1
- IYPYJVAROLJHPB-UHFFFAOYSA-N [4-(3-chlorophenyl)piperazin-1-yl]-(1-phenylimidazol-2-yl)methanone Chemical compound ClC1=CC=CC(N2CCN(CC2)C(=O)C=2N(C=CN=2)C=2C=CC=CC=2)=C1 IYPYJVAROLJHPB-UHFFFAOYSA-N 0.000 claims 1
- NOYBMSQOHYWIHO-UHFFFAOYSA-N [4-(3-chlorophenyl)piperazin-1-yl]-[1-[2-(dimethylamino)ethyl]-4-phenylpyrrol-3-yl]methanone Chemical compound C=1C=CC=CC=1C1=CN(CCN(C)C)C=C1C(=O)N(CC1)CCN1C1=CC=CC(Cl)=C1 NOYBMSQOHYWIHO-UHFFFAOYSA-N 0.000 claims 1
- PGBCNRJBTPSOKW-UHFFFAOYSA-N [4-(3-methoxyphenyl)piperazin-1-yl]-(2-phenylpyrazol-3-yl)methanone Chemical compound COC1=CC=CC(N2CCN(CC2)C(=O)C=2N(N=CC=2)C=2C=CC=CC=2)=C1 PGBCNRJBTPSOKW-UHFFFAOYSA-N 0.000 claims 1
- MJIAEQNZNAPBNG-UHFFFAOYSA-N [4-(4-amino-3-nitrophenyl)-2,5-dimethylfuran-3-yl]-(4-phenylpiperazin-1-yl)methanone Chemical compound CC=1OC(C)=C(C=2C=C(C(N)=CC=2)[N+]([O-])=O)C=1C(=O)N(CC1)CCN1C1=CC=CC=C1 MJIAEQNZNAPBNG-UHFFFAOYSA-N 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 229940017219 methyl propionate Drugs 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- WSDQIHATCCOMLH-UHFFFAOYSA-N phenyl n-(3,5-dichlorophenyl)carbamate Chemical compound ClC1=CC(Cl)=CC(NC(=O)OC=2C=CC=CC=2)=C1 WSDQIHATCCOMLH-UHFFFAOYSA-N 0.000 claims 1
- 150000003233 pyrroles Chemical class 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 522
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 225
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 204
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 135
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 111
- 238000001819 mass spectrum Methods 0.000 description 111
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 108
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 104
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 102
- 239000000741 silica gel Substances 0.000 description 95
- 229910002027 silica gel Inorganic materials 0.000 description 95
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 93
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 88
- 238000003818 flash chromatography Methods 0.000 description 86
- 238000003756 stirring Methods 0.000 description 74
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 69
- 238000000034 method Methods 0.000 description 69
- 239000007787 solid Substances 0.000 description 68
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 66
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 65
- 238000000746 purification Methods 0.000 description 63
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 57
- 239000000243 solution Substances 0.000 description 55
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 50
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 50
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 45
- 239000000047 product Substances 0.000 description 45
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 44
- 235000019341 magnesium sulphate Nutrition 0.000 description 44
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 39
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 37
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 36
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 33
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 32
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 30
- 239000003921 oil Substances 0.000 description 26
- 235000019198 oils Nutrition 0.000 description 26
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 25
- 239000012312 sodium hydride Substances 0.000 description 25
- 229910000104 sodium hydride Inorganic materials 0.000 description 25
- 238000010908 decantation Methods 0.000 description 24
- 238000001816 cooling Methods 0.000 description 22
- 230000008018 melting Effects 0.000 description 22
- 238000002844 melting Methods 0.000 description 22
- 239000012074 organic phase Substances 0.000 description 21
- 239000011541 reaction mixture Substances 0.000 description 20
- 239000013078 crystal Substances 0.000 description 19
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 18
- 239000007864 aqueous solution Substances 0.000 description 17
- 238000002425 crystallisation Methods 0.000 description 17
- COWMQOCYJSUFSB-UHFFFAOYSA-N 1-(3,5-dimethoxyphenyl)piperazine Chemical compound COC1=CC(OC)=CC(N2CCNCC2)=C1 COWMQOCYJSUFSB-UHFFFAOYSA-N 0.000 description 16
- 230000008025 crystallization Effects 0.000 description 16
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 16
- 239000002244 precipitate Substances 0.000 description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 12
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 12
- 239000002585 base Substances 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 238000010828 elution Methods 0.000 description 12
- 238000001953 recrystallisation Methods 0.000 description 12
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 12
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 11
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 11
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 238000001035 drying Methods 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000008346 aqueous phase Substances 0.000 description 9
- 238000004587 chromatography analysis Methods 0.000 description 9
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 9
- 239000003643 water by type Substances 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- UCDOBYGHVUULRO-UHFFFAOYSA-N 3-piperazin-1-ylbenzonitrile;dihydrochloride Chemical compound Cl.Cl.N#CC1=CC=CC(N2CCNCC2)=C1 UCDOBYGHVUULRO-UHFFFAOYSA-N 0.000 description 8
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- FEKRFYZGYUTGRY-UHFFFAOYSA-N n'-ethylmethanediimine Chemical compound CCN=C=N FEKRFYZGYUTGRY-UHFFFAOYSA-N 0.000 description 8
- 239000012429 reaction media Substances 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- 239000000377 silicon dioxide Substances 0.000 description 8
- GQTJEWBTNLPAFU-UHFFFAOYSA-N (3-piperazin-1-ylphenyl)methanol;dihydrochloride Chemical compound Cl.Cl.OCC1=CC=CC(N2CCNCC2)=C1 GQTJEWBTNLPAFU-UHFFFAOYSA-N 0.000 description 7
- VHFVKMTVMIZMIK-UHFFFAOYSA-N 1-(3-chlorophenyl)piperazine Chemical compound ClC1=CC=CC(N2CCNCC2)=C1 VHFVKMTVMIZMIK-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 244000309464 bull Species 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 150000004885 piperazines Chemical class 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- VICOSPWZPSCMHY-UHFFFAOYSA-N 2-methyl-4-phenyl-1h-imidazole-5-carboxylic acid Chemical compound N1C(C)=NC(C=2C=CC=CC=2)=C1C(O)=O VICOSPWZPSCMHY-UHFFFAOYSA-N 0.000 description 6
- VZTQYHRMGFZHQD-UHFFFAOYSA-N 5-phenyl-2-sulfanylidene-1,3-dihydroimidazole-4-carboxylic acid Chemical compound N1C(S)=NC(C=2C=CC=CC=2)=C1C(=O)O VZTQYHRMGFZHQD-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 102000004243 Tubulin Human genes 0.000 description 6
- 108090000704 Tubulin Proteins 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- VNKAOZFTIGAIPR-UHFFFAOYSA-N 2-amino-4-phenyl-1,3-thiazole-5-carboxylic acid Chemical compound S1C(N)=NC(C=2C=CC=CC=2)=C1C(O)=O VNKAOZFTIGAIPR-UHFFFAOYSA-N 0.000 description 5
- UICZVYGCGBFRTO-UHFFFAOYSA-N amino 2-(2-methoxyethyl)-4-phenyl-1,3-thiazole-5-carboxylate Chemical compound COCCC=1SC(=C(N=1)C1=CC=CC=C1)C(=O)ON UICZVYGCGBFRTO-UHFFFAOYSA-N 0.000 description 5
- 238000006116 polymerization reaction Methods 0.000 description 5
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 4
- 125000006016 2-bromoethoxy group Chemical group 0.000 description 4
- IIQFBTDWCPUWJG-UHFFFAOYSA-N 2-methylsulfonyl-4-phenyl-1h-imidazole-5-carboxylic acid Chemical compound N1C(S(=O)(=O)C)=NC(C=2C=CC=CC=2)=C1C(O)=O IIQFBTDWCPUWJG-UHFFFAOYSA-N 0.000 description 4
- OEUUDKWBUGDTGL-UHFFFAOYSA-N 2-phenyl-1h-pyrrole-3-carboxylic acid Chemical compound C1=CNC(C=2C=CC=CC=2)=C1C(=O)O OEUUDKWBUGDTGL-UHFFFAOYSA-N 0.000 description 4
- JKPQOHQTACWXPF-UHFFFAOYSA-N 3-phenyl-1h-pyrrole-2-carboxylic acid Chemical compound N1C=CC(C=2C=CC=CC=2)=C1C(=O)O JKPQOHQTACWXPF-UHFFFAOYSA-N 0.000 description 4
- LJUHEEFEADORHV-UHFFFAOYSA-N 3-piperazin-1-ylbenzonitrile Chemical compound N#CC1=CC=CC(N2CCNCC2)=C1 LJUHEEFEADORHV-UHFFFAOYSA-N 0.000 description 4
- FHNJGCZCAODEEQ-UHFFFAOYSA-N 3-piperazin-1-ylphenol;dihydrochloride Chemical compound Cl.Cl.OC1=CC=CC(N2CCNCC2)=C1 FHNJGCZCAODEEQ-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- 235000019502 Orange oil Nutrition 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- CVVIJWRCGSYCMB-UHFFFAOYSA-N hydron;piperazine;dichloride Chemical compound Cl.Cl.C1CNCCN1 CVVIJWRCGSYCMB-UHFFFAOYSA-N 0.000 description 4
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 4
- 239000010502 orange oil Substances 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- JBKINHFZTVLNEM-UHFFFAOYSA-N 2-bromoethoxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCCBr JBKINHFZTVLNEM-UHFFFAOYSA-N 0.000 description 3
- FWXHDKIZGOTPPF-UHFFFAOYSA-N 2-oxo-4-phenyl-3h-1,3-thiazole-5-carboxylic acid Chemical compound S1C(O)=NC(C=2C=CC=CC=2)=C1C(=O)O FWXHDKIZGOTPPF-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 3
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 3
- 239000012300 argon atmosphere Substances 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 150000002545 isoxazoles Chemical class 0.000 description 3
- 150000002825 nitriles Chemical class 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical class N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 3
- XKMLYUALXHKNFT-UHFFFAOYSA-N rGTP Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O XKMLYUALXHKNFT-UHFFFAOYSA-N 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- PMHHOXNLQZBSEY-UHFFFAOYSA-N tert-butyl 4-[3-(difluoromethoxy)phenyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=CC(OC(F)F)=C1 PMHHOXNLQZBSEY-UHFFFAOYSA-N 0.000 description 3
- 238000007280 thionation reaction Methods 0.000 description 3
- 150000008083 1,2,3,6-tetrahydropyridines Chemical class 0.000 description 2
- PZIBVWUXWNYTNL-UHFFFAOYSA-N 1-(3-methoxyphenyl)piperazine Chemical compound COC1=CC=CC(N2CCNCC2)=C1 PZIBVWUXWNYTNL-UHFFFAOYSA-N 0.000 description 2
- QIIFRFPHEWZBAQ-UHFFFAOYSA-N 1-[3-(difluoromethoxy)phenyl]piperazine;hydrochloride Chemical compound Cl.FC(F)OC1=CC=CC(N2CCNCC2)=C1 QIIFRFPHEWZBAQ-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- APXSARIYDLVPAY-UHFFFAOYSA-N 2-methyl-4-phenyl-1,3-thiazole-5-carboxylic acid Chemical compound S1C(C)=NC(C=2C=CC=CC=2)=C1C(O)=O APXSARIYDLVPAY-UHFFFAOYSA-N 0.000 description 2
- KHCXGFNZZRXOND-UHFFFAOYSA-N 3-(bromomethyl)pyridine Chemical compound BrCC1=CC=CN=C1 KHCXGFNZZRXOND-UHFFFAOYSA-N 0.000 description 2
- FNHPUOJKUXFUKN-UHFFFAOYSA-N 3-(bromomethyl)pyridine;hydron;bromide Chemical compound Br.BrCC1=CC=CN=C1 FNHPUOJKUXFUKN-UHFFFAOYSA-N 0.000 description 2
- CTNPDNGKELIMSR-UHFFFAOYSA-N 3-[4-(3-phenyl-1h-pyrrole-2-carbonyl)piperazin-1-yl]benzonitrile Chemical compound N1C=CC(C=2C=CC=CC=2)=C1C(=O)N(CC1)CCN1C1=CC=CC(C#N)=C1 CTNPDNGKELIMSR-UHFFFAOYSA-N 0.000 description 2
- JLHHKWVXXKRTCC-UHFFFAOYSA-N 3-[4-[1-[1-[tert-butyl(dimethyl)silyl]oxyethyl]-2-phenylpyrrole-3-carbonyl]piperazin-1-yl]benzamide Chemical compound C=1C=CC=CC=1C=1N(C(O[Si](C)(C)C(C)(C)C)C)C=CC=1C(=O)N(CC1)CCN1C1=CC=CC(C(N)=O)=C1 JLHHKWVXXKRTCC-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- NOJPHWCXWAYZFS-UHFFFAOYSA-N 3-piperazin-1-ylbenzamide Chemical compound NC(=O)C1=CC=CC(N2CCNCC2)=C1 NOJPHWCXWAYZFS-UHFFFAOYSA-N 0.000 description 2
- NGTZFWMOTDGMKO-UHFFFAOYSA-N 4-phenyl-1,3-thiazole-5-carboxylic acid Chemical compound S1C=NC(C=2C=CC=CC=2)=C1C(=O)O NGTZFWMOTDGMKO-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108091077621 MAPRE family Proteins 0.000 description 2
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- XRGLIKBSBFNEGC-UHFFFAOYSA-N [4-(3,5-dimethoxyphenyl)piperazin-1-yl]-(1-methyl-3-phenylpyrrol-2-yl)methanone;hydrochloride Chemical compound Cl.COC1=CC(OC)=CC(N2CCN(CC2)C(=O)C=2N(C=CC=2C=2C=CC=CC=2)C)=C1 XRGLIKBSBFNEGC-UHFFFAOYSA-N 0.000 description 2
- YHNLLCBHNKFMHP-UHFFFAOYSA-N [4-(3,5-dimethoxyphenyl)piperazin-1-yl]-(2-methylsulfinyl-4-phenyl-1h-imidazol-5-yl)methanone Chemical compound COC1=CC(OC)=CC(N2CCN(CC2)C(=O)C2=C(NC(=N2)S(C)=O)C=2C=CC=CC=2)=C1 YHNLLCBHNKFMHP-UHFFFAOYSA-N 0.000 description 2
- WXQISMMVKCREDF-UHFFFAOYSA-N [4-(3,5-dimethoxyphenyl)piperazin-1-yl]-(3-phenylimidazol-4-yl)methanone;hydrochloride Chemical compound Cl.COC1=CC(OC)=CC(N2CCN(CC2)C(=O)C=2N(C=NC=2)C=2C=CC=CC=2)=C1 WXQISMMVKCREDF-UHFFFAOYSA-N 0.000 description 2
- HOULBRYZTMTERN-UHFFFAOYSA-N [4-(3,5-dimethoxyphenyl)piperazin-1-yl]-[2-phenyl-1-(pyridin-3-ylmethyl)pyrrol-3-yl]methanone Chemical compound COC1=CC(OC)=CC(N2CCN(CC2)C(=O)C2=C(N(CC=3C=NC=CC=3)C=C2)C=2C=CC=CC=2)=C1 HOULBRYZTMTERN-UHFFFAOYSA-N 0.000 description 2
- PJLKWFYMRKEDTC-UHFFFAOYSA-N [4-(3-chlorophenyl)piperazin-1-yl]-(1-methyl-3-phenylpyrrol-2-yl)methanone Chemical compound CN1C=CC(C=2C=CC=CC=2)=C1C(=O)N(CC1)CCN1C1=CC=CC(Cl)=C1 PJLKWFYMRKEDTC-UHFFFAOYSA-N 0.000 description 2
- OPHMQDYMDVBYNH-UHFFFAOYSA-N [4-(3-chlorophenyl)piperazin-1-yl]-(3-phenylimidazol-4-yl)methanone Chemical compound ClC1=CC=CC(N2CCN(CC2)C(=O)C=2N(C=NC=2)C=2C=CC=CC=2)=C1 OPHMQDYMDVBYNH-UHFFFAOYSA-N 0.000 description 2
- DGIMBUOWKVIANE-UHFFFAOYSA-N [4-(3-chlorophenyl)piperazin-1-yl]-[1-[2-(dimethylamino)ethyl]-4-phenylpyrrol-3-yl]methanone;hydrochloride Chemical compound Cl.C=1C=CC=CC=1C1=CN(CCN(C)C)C=C1C(=O)N(CC1)CCN1C1=CC=CC(Cl)=C1 DGIMBUOWKVIANE-UHFFFAOYSA-N 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical group C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- QKCQVGUNUZJZKC-UHFFFAOYSA-N ethyl 2-methylsulfanyl-4-phenyl-1H-imidazole-5-carboxylate Chemical compound N1C(SC)=NC(C=2C=CC=CC=2)=C1C(=O)OCC QKCQVGUNUZJZKC-UHFFFAOYSA-N 0.000 description 2
- QYWSSFHUNRWYAW-UHFFFAOYSA-N ethyl 2-methylsulfonyl-4-phenyl-1h-imidazole-5-carboxylate Chemical compound N1C(S(C)(=O)=O)=NC(C=2C=CC=CC=2)=C1C(=O)OCC QYWSSFHUNRWYAW-UHFFFAOYSA-N 0.000 description 2
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000004922 lacquer Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 2
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 2
- SKULNZXRYGEWLW-UHFFFAOYSA-N methyl 2-[3-[4-(3,5-dimethoxyphenyl)piperazine-1-carbonyl]-2-phenylpyrrol-1-yl]acetate Chemical compound C=1C=CC=CC=1C=1N(CC(=O)OC)C=CC=1C(=O)N(CC1)CCN1C1=CC(OC)=CC(OC)=C1 SKULNZXRYGEWLW-UHFFFAOYSA-N 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 2
- QCQBXFHKXKLWFT-UHFFFAOYSA-N tert-butyl 4-(3-carbamoylphenyl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=CC(C(N)=O)=C1 QCQBXFHKXKLWFT-UHFFFAOYSA-N 0.000 description 2
- CAHGMTOVXFIRAF-UHFFFAOYSA-N tert-butyl 4-(3-cyanophenyl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=CC(C#N)=C1 CAHGMTOVXFIRAF-UHFFFAOYSA-N 0.000 description 2
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- QSLPNSWXUQHVLP-UHFFFAOYSA-N $l^{1}-sulfanylmethane Chemical compound [S]C QSLPNSWXUQHVLP-UHFFFAOYSA-N 0.000 description 1
- CDBOBDXTCRCJJA-UHFFFAOYSA-N (2-amino-4-phenyl-1,3-thiazol-5-yl)-[4-(3,5-dimethoxyphenyl)piperazin-1-yl]methanone Chemical compound COC1=CC(OC)=CC(N2CCN(CC2)C(=O)C2=C(N=C(N)S2)C=2C=CC=CC=2)=C1 CDBOBDXTCRCJJA-UHFFFAOYSA-N 0.000 description 1
- RBSSPJDOINFUCR-UHFFFAOYSA-N 1-(3,5-dimethylphenyl)piperazine Chemical compound CC1=CC(C)=CC(N2CCNCC2)=C1 RBSSPJDOINFUCR-UHFFFAOYSA-N 0.000 description 1
- WEZRSRLKOVMNRG-UHFFFAOYSA-N 1-[3-(difluoromethoxy)phenyl]piperazine;dihydrochloride Chemical compound Cl.Cl.FC(F)OC1=CC=CC(N2CCNCC2)=C1 WEZRSRLKOVMNRG-UHFFFAOYSA-N 0.000 description 1
- NWBDGKNKAFGQQL-UHFFFAOYSA-N 1-bromo-3-(difluoromethoxy)benzene Chemical compound FC(F)OC1=CC=CC(Br)=C1 NWBDGKNKAFGQQL-UHFFFAOYSA-N 0.000 description 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
- KPTMLRRGBKWXAB-UHFFFAOYSA-N 1-methyl-2-phenylpyrrole-3-carboxylic acid Chemical compound CN1C=CC(C(O)=O)=C1C1=CC=CC=C1 KPTMLRRGBKWXAB-UHFFFAOYSA-N 0.000 description 1
- DNDJHEWLYGJJCY-UHFFFAOYSA-N 1-pyridin-3-ylpiperazine Chemical compound C1CNCCN1C1=CC=CN=C1 DNDJHEWLYGJJCY-UHFFFAOYSA-N 0.000 description 1
- FJFVSKLYCLSKPN-UHFFFAOYSA-N 2-(3-piperazin-1-ylphenyl)acetonitrile;dihydrochloride Chemical compound Cl.Cl.N#CCC1=CC=CC(N2CCNCC2)=C1 FJFVSKLYCLSKPN-UHFFFAOYSA-N 0.000 description 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- LQLJZSJKRYTKTP-UHFFFAOYSA-N 2-dimethylaminoethyl chloride hydrochloride Chemical compound Cl.CN(C)CCCl LQLJZSJKRYTKTP-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- WIVXJYKYHMLEEO-UHFFFAOYSA-N 2-oxo-5-phenyl-1,3-dihydroimidazole-4-carboxylic acid Chemical compound N1C(=O)NC(C=2C=CC=CC=2)=C1C(=O)O WIVXJYKYHMLEEO-UHFFFAOYSA-N 0.000 description 1
- HQQHXNRWOJWVHF-UHFFFAOYSA-N 3-(4-chlorophenyl)furan-2-carboxylic acid Chemical compound O1C=CC(C=2C=CC(Cl)=CC=2)=C1C(=O)O HQQHXNRWOJWVHF-UHFFFAOYSA-N 0.000 description 1
- NDQQGQAFMKEMSD-UHFFFAOYSA-N 3-(bromomethyl)pyridin-1-ium;chloride Chemical compound Cl.BrCC1=CC=CN=C1 NDQQGQAFMKEMSD-UHFFFAOYSA-N 0.000 description 1
- QXGYJWXBMJDQGZ-UHFFFAOYSA-N 3-[4-(2-oxo-4-phenyl-3h-1,3-thiazole-5-carbonyl)piperazin-1-yl]benzamide Chemical compound NC(=O)C1=CC=CC(N2CCN(CC2)C(=O)C2=C(N=C(O)S2)C=2C=CC=CC=2)=C1 QXGYJWXBMJDQGZ-UHFFFAOYSA-N 0.000 description 1
- IHGGRCBIVYDSME-UHFFFAOYSA-N 3-[4-(2-phenyl-1h-pyrrole-3-carbonyl)piperazin-1-yl]benzamide Chemical compound NC(=O)C1=CC=CC(N2CCN(CC2)C(=O)C2=C(NC=C2)C=2C=CC=CC=2)=C1 IHGGRCBIVYDSME-UHFFFAOYSA-N 0.000 description 1
- CIQKUWDCOUCJRU-UHFFFAOYSA-N 3-[4-[1-(1-hydroxyethyl)-4-phenylpyrrole-3-carbonyl]piperazin-1-yl]benzamide Chemical compound C=1C=CC=CC=1C1=CN(C(O)C)C=C1C(=O)N(CC1)CCN1C1=CC=CC(C(N)=O)=C1 CIQKUWDCOUCJRU-UHFFFAOYSA-N 0.000 description 1
- QTFXKXCYJDYQDY-UHFFFAOYSA-N 3-[4-[1-[1-[tert-butyl(dimethyl)silyl]oxyethyl]-2-phenylpyrrole-3-carbonyl]piperazin-1-yl]benzonitrile Chemical compound C=1C=CC=CC=1C=1N(C(O[Si](C)(C)C(C)(C)C)C)C=CC=1C(=O)N(CC1)CCN1C1=CC=CC(C#N)=C1 QTFXKXCYJDYQDY-UHFFFAOYSA-N 0.000 description 1
- MYIPWURFMVUESE-UHFFFAOYSA-N 3-[4-[1-[1-[tert-butyl(dimethyl)silyl]oxyethyl]-4-phenylpyrrole-3-carbonyl]piperazin-1-yl]benzamide Chemical compound C=1C=CC=CC=1C1=CN(C(O[Si](C)(C)C(C)(C)C)C)C=C1C(=O)N(CC1)CCN1C1=CC=CC(C(N)=O)=C1 MYIPWURFMVUESE-UHFFFAOYSA-N 0.000 description 1
- MKUBEKJYHLLGIG-UHFFFAOYSA-N 3-[4-[1-[1-[tert-butyl(dimethyl)silyl]oxyethyl]-4-phenylpyrrole-3-carbonyl]piperazin-1-yl]benzonitrile Chemical compound C=1C=CC=CC=1C1=CN(C(O[Si](C)(C)C(C)(C)C)C)C=C1C(=O)N(CC1)CCN1C1=CC=CC(C#N)=C1 MKUBEKJYHLLGIG-UHFFFAOYSA-N 0.000 description 1
- STXAVEHFKAXGOX-UHFFFAOYSA-N 3-bromobenzonitrile Chemical compound BrC1=CC=CC(C#N)=C1 STXAVEHFKAXGOX-UHFFFAOYSA-N 0.000 description 1
- KWWGBNRBZMJKPA-UHFFFAOYSA-N 3-phenylthiophene-2-carboxylic acid Chemical compound S1C=CC(C=2C=CC=CC=2)=C1C(=O)O KWWGBNRBZMJKPA-UHFFFAOYSA-N 0.000 description 1
- HUUNJDIASCEFMX-UHFFFAOYSA-N 3-piperazin-1-ylbenzamide;dihydrochloride Chemical compound Cl.Cl.NC(=O)C1=CC=CC(N2CCNCC2)=C1 HUUNJDIASCEFMX-UHFFFAOYSA-N 0.000 description 1
- MLTNLTOQFCXOAG-UHFFFAOYSA-N 4-(3,5-dimethoxyphenyl)piperazine-1-carbaldehyde Chemical compound COC=1C=C(C=C(C=1)OC)N1CCN(CC1)C=O MLTNLTOQFCXOAG-UHFFFAOYSA-N 0.000 description 1
- ZKFDBRDGCUBXDP-UHFFFAOYSA-N 4-(3-cyanophenyl)piperazine-1-carboxylic acid Chemical compound C1CN(C(=O)O)CCN1C1=CC=CC(C#N)=C1 ZKFDBRDGCUBXDP-UHFFFAOYSA-N 0.000 description 1
- NVTBASMQHFMANH-UHFFFAOYSA-N 4-(chloromethyl)-1,3-thiazole;hydron;chloride Chemical compound Cl.ClCC1=CSC=N1 NVTBASMQHFMANH-UHFFFAOYSA-N 0.000 description 1
- GWRSATNRNFYMDI-UHFFFAOYSA-N 4-[(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-2-fluoro-5-methoxy-n-(1-methylpiperidin-4-yl)benzamide Chemical compound FC=1C=C(NC=2N=C3N(C4CCCC4)CC(F)(F)C(=O)N(C)C3=CN=2)C(OC)=CC=1C(=O)NC1CCN(C)CC1 GWRSATNRNFYMDI-UHFFFAOYSA-N 0.000 description 1
- PYSJLPAOBIGQPK-UHFFFAOYSA-N 4-phenyl-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C=CC=CC=2)=C1 PYSJLPAOBIGQPK-UHFFFAOYSA-N 0.000 description 1
- UXIWLHNMLDJWMF-UHFFFAOYSA-N 4-phenyl-3h-1,3-thiazol-2-one Chemical compound S1C(O)=NC(C=2C=CC=CC=2)=C1 UXIWLHNMLDJWMF-UHFFFAOYSA-N 0.000 description 1
- VRJHQPZVIGNGMX-UHFFFAOYSA-N 4-piperidinone Chemical class O=C1CCNCC1 VRJHQPZVIGNGMX-UHFFFAOYSA-N 0.000 description 1
- RUKDIKJSGDVSIF-UHFFFAOYSA-N 5-phenyl-1,3-oxazole-4-carboxylic acid Chemical compound N1=COC(C=2C=CC=CC=2)=C1C(=O)O RUKDIKJSGDVSIF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- LPYPTPFNWAOZOL-UHFFFAOYSA-N CC(N1C=CC=C1C2=CC=CC=C2)O[Si](C)(C)C(C)(C)C Chemical compound CC(N1C=CC=C1C2=CC=CC=C2)O[Si](C)(C)C(C)(C)C LPYPTPFNWAOZOL-UHFFFAOYSA-N 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 102000005454 Dimethylallyltranstransferase Human genes 0.000 description 1
- 108010006731 Dimethylallyltranstransferase Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 229940123583 Factor Xa inhibitor Drugs 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000394605 Viola striata Species 0.000 description 1
- FXECOFBSHWFXSB-UHFFFAOYSA-N [1-[2-[tert-butyl(dimethyl)silyl]oxyethyl]-4-phenylpyrrol-3-yl]-[4-(3,5-dimethoxyphenyl)piperazin-1-yl]methanone Chemical compound COC1=CC(OC)=CC(N2CCN(CC2)C(=O)C=2C(=CN(CCO[Si](C)(C)C(C)(C)C)C=2)C=2C=CC=CC=2)=C1 FXECOFBSHWFXSB-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UDIABACLSA-N [14C@@H]1(C[C@H](O)[C@@H](CO)O1)N1C(=O)NC(=O)C(C)=C1 Chemical compound [14C@@H]1(C[C@H](O)[C@@H](CO)O1)N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-UDIABACLSA-N 0.000 description 1
- KFOWJXRKNNZZHQ-UHFFFAOYSA-N [3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]methanone Chemical compound CC=1ON=C(C=2C(=CC=CC=2Cl)Cl)C=1C(=O)N(CC1)CCN1C1=CC=CC(C(F)(F)F)=C1 KFOWJXRKNNZZHQ-UHFFFAOYSA-N 0.000 description 1
- DZALIPAMTSBMQL-UHFFFAOYSA-N [4-(3,5-dimethoxyphenyl)piperazin-1-yl]-(1-methyl-4-phenylpyrrol-3-yl)methanone;hydrochloride Chemical compound Cl.COC1=CC(OC)=CC(N2CCN(CC2)C(=O)C=2C(=CN(C)C=2)C=2C=CC=CC=2)=C1 DZALIPAMTSBMQL-UHFFFAOYSA-N 0.000 description 1
- DCTFAUOATIBRAU-UHFFFAOYSA-N [4-(3,5-dimethoxyphenyl)piperazin-1-yl]-(2-methoxy-4-phenyl-1,3-thiazol-5-yl)methanone Chemical compound S1C(OC)=NC(C=2C=CC=CC=2)=C1C(=O)N(CC1)CCN1C1=CC(OC)=CC(OC)=C1 DCTFAUOATIBRAU-UHFFFAOYSA-N 0.000 description 1
- CLVGDIPNPQWNLK-UHFFFAOYSA-N [4-(3,5-dimethoxyphenyl)piperazin-1-yl]-(5-phenyl-2-sulfanylidene-1,3-dihydroimidazol-4-yl)methanone Chemical compound COC1=CC(OC)=CC(N2CCN(CC2)C(=O)C2=C(NC(S)=N2)C=2C=CC=CC=2)=C1 CLVGDIPNPQWNLK-UHFFFAOYSA-N 0.000 description 1
- XQPNKEKARXSECS-UHFFFAOYSA-N [4-[3-(hydroxymethyl)phenyl]piperazin-1-yl]-(2-methylsulfanyl-4-phenyl-1h-imidazol-5-yl)methanone Chemical compound N1C(SC)=NC(C=2C=CC=CC=2)=C1C(=O)N(CC1)CCN1C1=CC=CC(CO)=C1 XQPNKEKARXSECS-UHFFFAOYSA-N 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 108020004102 alpha-1 Adrenergic Receptor Proteins 0.000 description 1
- 102000015009 alpha1-adrenergic receptor activity proteins Human genes 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- 238000006254 arylation reaction Methods 0.000 description 1
- 229940090047 auto-injector Drugs 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000002946 cyanobenzyl group Chemical group 0.000 description 1
- JEVCWSUVFOYBFI-UHFFFAOYSA-N cyanyl Chemical compound N#[C] JEVCWSUVFOYBFI-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 125000005805 dimethoxy phenyl group Chemical group 0.000 description 1
- JZBWUTVDIDNCMW-UHFFFAOYSA-L dipotassium;oxido sulfate Chemical compound [K+].[K+].[O-]OS([O-])(=O)=O JZBWUTVDIDNCMW-UHFFFAOYSA-L 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- GMUXVPNXBVLTCG-UHFFFAOYSA-N ethyl 2-methyl-4-phenyl-1h-imidazole-5-carboxylate Chemical compound N1C(C)=NC(C=2C=CC=CC=2)=C1C(=O)OCC GMUXVPNXBVLTCG-UHFFFAOYSA-N 0.000 description 1
- KUVOQWRTXPCJOZ-UHFFFAOYSA-N ethyl 2-oxo-4-phenyl-3h-1,3-thiazole-5-carboxylate Chemical compound S1C(=O)NC(C=2C=CC=CC=2)=C1C(=O)OCC KUVOQWRTXPCJOZ-UHFFFAOYSA-N 0.000 description 1
- XBPOBCXHALHJFP-UHFFFAOYSA-N ethyl 4-bromobutanoate Chemical compound CCOC(=O)CCCBr XBPOBCXHALHJFP-UHFFFAOYSA-N 0.000 description 1
- NGMYKWXFKDHMJY-UHFFFAOYSA-N ethyl 5-phenyl-2-sulfanylidene-1,3-dihydroimidazole-4-carboxylate Chemical compound N1C(=S)NC(C=2C=CC=CC=2)=C1C(=O)OCC NGMYKWXFKDHMJY-UHFFFAOYSA-N 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- JKFAIQOWCVVSKC-UHFFFAOYSA-N furazan Chemical compound C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- GOVYTZKYELJVRT-UHFFFAOYSA-N methyl 2-[2-[4-(3-cyanophenyl)piperazine-1-carbonyl]-3-phenylpyrrol-1-yl]acetate Chemical compound COC(=O)CN1C=CC(C=2C=CC=CC=2)=C1C(=O)N(CC1)CCN1C1=CC=CC(C#N)=C1 GOVYTZKYELJVRT-UHFFFAOYSA-N 0.000 description 1
- UPAGPWKZSOOAHP-UHFFFAOYSA-N methyl 2-[3-[4-(3-carbamoylphenyl)piperazine-1-carbonyl]-4-phenyl-1h-pyrrol-2-yl]acetate Chemical compound COC(=O)CC=1NC=C(C=2C=CC=CC=2)C=1C(=O)N(CC1)CCN1C1=CC=CC(C(N)=O)=C1 UPAGPWKZSOOAHP-UHFFFAOYSA-N 0.000 description 1
- KQEVIFKPZOGBMZ-UHFFFAOYSA-N methyl 3-bromopropanoate Chemical compound COC(=O)CCBr KQEVIFKPZOGBMZ-UHFFFAOYSA-N 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- PSAHTRPCKTWOAH-UHFFFAOYSA-N n-(3-piperazin-1-ylphenyl)acetamide Chemical compound CC(=O)NC1=CC=CC(N2CCNCC2)=C1 PSAHTRPCKTWOAH-UHFFFAOYSA-N 0.000 description 1
- ODUCDPQEXGNKDN-UHFFFAOYSA-N nitroxyl Chemical compound O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 125000001979 organolithium group Chemical group 0.000 description 1
- 125000002734 organomagnesium group Chemical group 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229940080469 phosphocellulose Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229960001289 prazosin Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- CSRCBLMBBOJYEX-UHFFFAOYSA-M sodium;2-morpholin-4-ylethanesulfonic acid;hydroxide Chemical compound [OH-].[Na+].OS(=O)(=O)CCN1CCOCC1 CSRCBLMBBOJYEX-UHFFFAOYSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Definitions
- the present invention relates to novel chemical compounds, particularly novel aryl-heteroaromatic products, compositions containing them, and their use as medicaments. More particularly, the invention relates, in a first aspect, to new aryl-heteroaromatic products exhibiting anticancer activity, and in particular tubulin polymerization inhibitory activity.
- the 1,2,5-oxadiazole is optionally in the form of an N-oxide.
- R is phenyl. Identified Products [CAS Numbers]: [157066-46-1], [157066-44-9], [157066-43-8], [157066-42-7].
- Patent Application WO 02/30927 discloses an isoxazole derivative on page 95; N- (4- ⁇ 4- [3- (2-chloro-phenyl) -5-methyl-isoxazole-4-carbonyl] -piperazin-1-yl ⁇ -phenyl) -N- [3- (cyano-benzyl) ) -3-H-imidazol-4-yl-methyl] -benzamide.
- This product described as prenyl transferase protein inhibitor and its use are not part of the present invention.
- WO 04/002965 published after the priority date of the present application, discloses piperazine derivatives useful for the treatment of cancer. All the products described in this patent application (17) are excluded from the present invention. Products with CAS number: 522598-56-7, 505088- 40-4,
- A is N or C; 2) LGR 11 eesstt cchhooiissii pplormmii and
- X and Y are independently selected from CR3, N, NR3, O or S; 4) E is CR4, N, NR4 or S;
- R1, R2 are independently selected from the group consisting of aryl, heteroaryl, substituted aryl, substituted heteroaryl;
- R3, R4 are independently selected from the group consisting of H, alyl, substituted alkyl, cycloalkyl, cycloalkylene, heterocyclyl, O-R7, S-R7, SO-R7, SO 2 - (R7), N (R7) (R8), halogen, aryl, heteroaryl, substituted cycloalkyl, substituted aryl, substituted heteroaryl;
- R5, R6 are independently selected from the group consisting of H, (C1-C3) alkyl
- R7, R8 are independently selected from the group consisting of H, (C1-C3) alkyl, (C1-C3) substituted alkyl; in racemic form, enriched in an enantiomer, enriched in a diastereoisomer, its tautomers, its prodrugs and its pharmaceutically acceptable salts, provided that the product of formula (I) is not one of the following compounds:
- A is N or C
- LG-R1 is selected from are preferred.
- a preferred substituent R 1 may be selected from phenyl, phenyl substituted with at least one radical selected from halogen, CF 3, CN, NO 2, (C 1 -C 3) -alkyl, O-R 10, S-R 10, N (R 10) (R 11) ,
- R10, R11 are independently selected from H, (C1-C3) -alkyl, (C1-C3) -alkyl halogen, (C1-C3) -alkyl-OH, (C1-C3) -alkyl-NH2, (C1-C3) -alkyl-COOH, (C1-C3) -alkyl-OCH3, (C1-C3) -alkyl-NHCH3, pyridyl, pyridyl substituted with at least one radical selected from halogen, (C1-C3) alkyl, O-R12, S-R12, N (R12) (
- R 1 will be 3-substituted phenyl by halogen or (C 1 -C 3) -alkyl, (C 1 -C 3) -alkoxy, (C 1 -C 3) alkylamino, CONH 2, CO-NH- (CH 2) 2 -OH or NH-CO-CH3; or 3-pyridyl .; 2- or 3-pyridyl substituted with halogen, (C1-C3) -alkyl or (C1 -C3) -alkoxy.
- R 1 is substituted phenyl
- preferred combinations of substitution may be selected from 2,3-disubstituted phenyl, 2,5-disubstituted phenyl, 3-substituted phenyl, 3,5-disubstituted phenyl, 3,4-phenyl disubstituted, more preferentially among 3-substituted-phenyl, 3,5-disubstituted phenyl, 3,4-disubstituted phenyl.
- R 1 is 2-pyridyl
- preferred substitutions are selected from 2-pyridyl-4- or 6-substituted or 2-pyridyl-4,6-disubstituted.
- R 1 is 3-pyridyl
- preferred substitutions are 3-pyridyl-2- or
- R 1 is phenyl substituted in the 3-position with a chloro radical or at the 3-position and 5-position with two methoxy radicals.
- R 1 is phenyl substituted at the 3-position with a cyano radical, a carboxamide radical, a methoxy radical, or a hydroxymethyl radical.
- a preferred substituent R2 may be selected from phenyl, phenyl substituted with at least one radical selected from halogen, alkyl, O-R10, S-R10, N (R10) (R11), wherein R10, R11 are independently selected from H, alkyl, halogenated alkyl; or 3-pyridyl.
- a preferred substituent R 1 is selected from 3-methoxyphenyl, 3,5-dimethoxyphenyl, and 3-carboxamidophenyl.
- a more preferred substituent R 1 is 3-carboxamidophenyl. Indeed, this substituent allows a significant improvement in the pharmacological properties of the products according to the invention.
- Products according to the first aspect of the invention wherein X is C, and Y is CR3 are particularly preferred. These features make it possible to highlight significantly improved pharmacological properties compared with other derivatives, such as better activity in vivo or in vitro, a better pharmacokinetic profile, a better pharmacodynamic profile, an increased ease of preparation, or better bioavailability such as orally, or iv
- the invention relates to pharmaceutical compositions comprising a product according to its first aspect, in combination with a pharmaceutically acceptable excipient.
- a product according to the invention can be advantageously used as a tubulin polymerization inhibiting agent, as an agent inhibiting the proliferation of tumor cells, to promote the disintegration of cell clusters originating from a vascular tissue, or for the manufacture of a drug useful for treating a pathological condition, preferably cancer.
- products of general formula (Ia) or (Ib) according to the invention in which L is C (O) may be prepared by coupling of an ortho-substituted heteroarylcarboxylic acid of the carboxylic function with an aryl radical.
- heteroaryl, of general formula (II) in which A, X, Y, E and R2 are defined as above, with, respectively, a piperazine derivative of general formula (IIIa) or a derivative of 1,2,3 , 6-tetrahydropyridine of the general formula (IIIb), in which R1 is defined as previously according to scheme 1:
- X, Y, E and R2 are defined as above, are commercial or can be obtained according to the general methods of synthesis known to those skilled in the art.
- R6 are defined as above, are either commercial or prepared according to conventional methods known to those skilled in the art.
- N1-aryl (heteroaryl) ation according to scheme 2, of piperazines bearing a protective group on nitrogen 4, is particularly advantageous in the context of the invention:
- aryl (heteroaryl) reaction of piperazines can be carried out under the conditions described in Biorg. Med. Chem. Leti, 11, 1375 (2001) or in Biorg. Med. Chem., 10, 3817 (2002).
- Another method for synthesizing aryl (heteroaryl) piperazines, particularly advantageous in the context of the invention, when R 5 and R 6 represent hydrogen atoms, consists in reacting an aryl (heteroaryl) amine with a bis ( 2-hydroxy- or 2-haloethyl) amine, at a temperature above 100-120 ° C according to scheme 3: OH (Hal)
- the 1,2,3,6-tetrahydropyridine derivatives (IIIb), in which R 1, R 5 and R 6 are defined as above, are either commercial or prepared according to conventional methods known to those skilled in the art.
- the action, according to scheme 4, of an organometallic derivative of aryl (heteroaryl), such as an organomagnesium, an organolithium or an organoceriac, on a piperidin-4-one derivative whose atom nitrogen is substituted with a protecting group is particularly advantageous.
- products of general formula (Ia) or (Ib) according to the invention in which L is C (S) may be prepared by thionation of a compound of general formula respectively (Ia) or (Ib), wherein L is C (O), by any of the thionation methods known to those skilled in the art, operating according to Scheme 6:
- products of general formula (Ia) or (Ib) according to the invention in which L is C (NH) may be prepared from nitriles derived from the products of general formula (II), using the various methods known to those skilled in the art, according to the reaction sequences of Scheme 7:
- products of general formula (Ia) according to the invention in which L is C (NR7), with R7 equal to or different from the hydrogen atom can be prepared from products of general formula ( la) in which L is C (O) and / or C (S), using the various methods known to those skilled in the art, according to the reaction sequences of scheme 8:
- X is an oxygen atom
- products in accordance with the invention can also be prepared on a solid phase, according to reaction scheme 9:
- LC / MS Purification The products were purified by LC / MS using a Waters FractionsLynx system consisting of a Waters Model 600 gradient pump, a Waters Model 515 regeneration pump, a Waters Reagent dilution pump Manager, Waters model 2700 auto-injector, two Rheodyne Model LabPro valves, a Model 996 Waters diode array detector, a Waters model ZMD mass spectrometer and a Gilson model 204 fraction collector The system was controlled by the Waters FractionLynx software.
- the separation was carried out alternately on two Waters Symmetry columns (C- ⁇ 8 , 5 ⁇ M, 19 ⁇ 50 mm, catalog number 186000210), a column being regenerated by a 95/5 (v / v) water / acetonitrile mixture containing 0 , 07% (v / v) of acid trifluoroacetic, while the other column was being separated. Elution of the columns was performed using a linear gradient of 5-95% acetonitrile containing 0.07% (v / v) trifluoroacetic acid in water containing 0.07% (v / v) d. trifluoroacetic acid at a flow rate of 10 ml / min.
- one thousandth of the effluent is separated by an LC Packing Accurate, diluted with methyl alcohol at a flow rate of 0.5 mL / min and sent to the detectors, at a rate of 75%. to the diode array detector, and the remaining 25% to the mass spectrometer.
- the remainder of the effluent (999/1000) is sent to the fraction collector where the flow is eliminated until the mass of the expected product is detected by the FractionLynx software.
- the molecular formulas of the expected products are provided to the FractionLynx software which triggers the product collection when the detected mass signal corresponds to the [M + H] + and / or [M + Na] + ion.
- the LC / MS analyzes were performed on a Micromass LCT model connected to an HP 1100.
- the abundance of the products was measured using an HP G1315A diode array detector over a range of 200-600 nm and a Sedex 65 light scattering detector.
- Mass spectra mass spectra were acquired over a range of 180 to 800. The data were analyzed using the Micromass MassLynx software.
- the separation was carried out on a Hypersil BDS C18 column, 3 ⁇ m (50 ⁇ 4.6 mm), eluting with a linear gradient of 5 to 90% of acetonitrile containing 0.05% (v / v) of trifluoroacetic acid ( TFA) in water containing 0.05% (v / v) TFA in 3.5 min at a flow rate of 1 mL / min.
- the total analysis time, including the rebalancing period of the column, is 7 minutes.
- Example 1 [4- (3-Chloro-phenyl) -piperazin-1-yl] - (1-phenyl-1H-imidazol-5-yl) -methanone Step 1: In a 100 ml three-necked flask, 3.5 g of ethyl 1-phenyl-1-H-imidazol-5-yl-carboxylate, which can be prepared according to Tetrahedron Lett, are dissolved. (2000) 41, 5453-56, in 50 mL of ethanol, then 25 mL of water and 16.2 mL of an 85% aqueous potassium hydroxide solution are added, followed by stirring for 20 hours at room temperature.
- reaction medium is taken up in 100 ml of water and then washed 3 times with 75 ml of diethyl ether.
- the aqueous phase is concentrated in vacuo and the residue is taken up in 10 ml of methanol and then filtered.
- the filtrate is finally taken up in 25 ml of isopropyl ether, drained and washed twice with 2 ml of isopropyl ether.
- 1-phenyl-1-H-imidazol-5-yl-carboxylic acid in the form of a brown solid, used as such in the next step.
- Step 2 In a 100 mL tricolor under an argon atmosphere, to a solution of 0.5 g of 1-phenyl-1-H-imidazole-5-yl-carboxylic acid in 25 mL of dichloromethane, are added successively 342 ⁇ l of oxalyl chloride and a few drops of dimethylformamide are stirred for 2 hours at room temperature. The solution thus obtained is transferred into a dropping funnel, and is added, dropwise, to a solution, cooled to 0 ° C. under an argon atmosphere, of 575 mg of 1- (3-chlorophenyl) piperazine in 25 ml.
- Step 1 By operating as in step 2 of Example 1, but starting from 350 mg of ethyl 4-phenyl-1-H-imidazol-5-yl-carboxylate - which can be prepared according to Tetrahedron Lett. . (1994), 35, 1635-38 and 1.6 ml of an 85% aqueous potassium hydroxide solution in 5 ml of ethanol and 2.5 ml of water give 218 mg of 4- phenyl-1-H-imidazol-5-yl-carboxylic acid, in the form of a beige solid used as it is in the next step.
- Step 2 By operating as in step 2 of Example 1, but starting from a portion of 188 mg of 4-phenyl-1-H-imidazol-5-yl-carboxylic acid and 128 ⁇ l of oxalyl chloride in 10 ml of dichloromethane, and on the other hand 216 mg of 1- (3-chlorophenyl) piperazine in 10 ml of dichloromethane containing 210 ⁇ l of triethylamine and 5 ⁇ l of 4-dimethylaminopyridine, for 20 hours at room temperature.
- Step 2 The procedure is as in Step 2 of Example 1, but in a stem tube of 10 mL under argon and from 80 mg of 3-phenyl-1H-pyrrol-2-yl-carboxylic acid. and 112 ⁇ l of oxalyl chloride in 5 ml of dichloromethane.
- the reaction medium is concentrated under reduced pressure, and the acid chloride thus obtained is dissolved in 5 ml of tetrahydrofuran, and then 76.3 mg of 3-chloro-phenyl) piperazine and 81.8 ⁇ l of triethylamine and then stirred for 20 hours at room temperature.
- the crude product is purified by LCMS according to the procedure described above.
- Example 5 The procedure is as in Example 5, but starting with 1 g of 4-phenyl-1-H-imidazol-5-yl-carboxylic acid, obtained in step 1 of Example 3, and 1.2 g of 1- (3,5-dimethoxy-phenyl) piperazine in 90 ml of dichloromethane in the presence of 1.1 g of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI) and 0.79 g of 1-hydroxybenzotriazole hydrate (HOBT), with stirring at room temperature for 48 hours.
- EDCI 1-(2-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride
- HOBT 1-hydroxybenzotriazole hydrate
- Example 5 The procedure is as in Example 5, but starting from 580 mg of 1-phenyl-1-H-imidazol-5-yl-carboxylic acid, obtained in step 1 of Example 1, and 685 mg of 1- (3,5-dimethoxy-phenyl) piperazine in 50 ml of dichloromethane, in the presence of 650 mg of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI) and 460 mg of 1-hydroxybenzotriazole hydrate (HOBT), with stirring at room temperature for 48 hours.
- EDCI 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride
- HOBT 1-hydroxybenzotriazole hydrate
- Example 5 The procedure is as in Example 5, but starting from 376 mg of 1-phenyl-1-H-imidazol-5-yl-carboxylic acid, obtained in step 1 of example 1, and 520 mg of 1- (3-cyano-phenyl) piperazine, which can be prepared according to Tetrahedron Lett. (2000), 56 (24), 4107-10, in 34 mL of dichloromethane, in the presence of 422 mg of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI) and 297 mg of 1-hydrate. hydroxybenzotriazole (HOBT), with stirring at room temperature for 20 hours.
- EDCI 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride
- HOBT hydroxybenzotriazole
- Example 5 The procedure is as in Example 5, but starting with 200 mg of 4-phenyl-1-H-imidazol-5-yl-carboxylic acid, obtained in step 1 of Example 3, and 276 mg of 1- (3-cyano-phenyl) piperazine, which can be prepared according to Tetrahedron Lett. (2000), 56 (24), 4107-10, in 34 mL of dichloromethane, in the presence of 224 mg of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI) and 158 mg of 1-hydrate. hydroxybenzotriazole (HOBT), with stirring at room temperature for 20 hours.
- EDCI 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride
- HOBT hydroxybenzotriazole
- Example 5 The procedure is as in Example 5, but starting from 562 mg of 4-phenyl-1-H-pyrrole-3-yl-carboxylic acid, which can be prepared according to Med. Chem. Res. (1997), 7 (2), 98-108, and 590 mg of 1- (3-chlorophenyl) piperazine in 90 ml of dichloromethane, in the presence of 632 mg of 1- (3-dimethylaminopropyl) hydrochloride. 3-ethylcarbodiimide (EDCI) and 446 mg of 1-hydroxybenzotriazole hydrate (HOBT), with stirring at room temperature for 72 hours.
- EDCI 3-ethylcarbodiimide
- HOBT 1-hydroxybenzotriazole hydrate
- Example 5 The procedure is as in Example 5, but starting from 201 mg of 1-methyl-4-phenyl-1-H-pyrrole-3-yl-carboxylic acid, which can be prepared according to Med. Chem. Res. (1997), 7 (2), 98-108, and 222 mg of 1- (3,5-dimethoxyphenyl) piperazine in 20 ml of dichloromethane, in the presence of 211 mg of 1- (3-dimethylaminopropyl) hydrochloride. ) -3-ethylcarbodiimide (EDCI) and 148 mg of 1-hydroxybenzotriazole hydrate (HOBT), with stirring at room temperature for 72 hours.
- EDCI 1-methyl-4-phenyl-1-H-pyrrole-3-yl-carboxylic acid
- Example 5 The procedure is as in Example 5, but starting from 200 mg of 2-mercapto-5-phenyl-1-H-imidazol-4-yl-carboxylic acid, which can be prepared according to Chem. Pharm. Bull. (1984), 32 (7), 2536-43, and 178.6 mg of 1- (3-chlorophenyl) piperazine in 15 mL of dichloromethane, in the presence of 192 mg of 1- (3-dimethylaminopropyl) hydrochloride. ) -3-ethylcarbodiimide (EDCI) and 135 mg of 1-hydroxybenzotriazole hydrate (HOBT), with stirring at room temperature for 24 hours. After concentration under reduced pressure, 20 ml of water are added.
- 2-mercapto-5-phenyl-1-H-imidazol-4-yl-carboxylic acid which can be prepared according to Chem. Pharm. Bull. (1984), 32 (7), 2536-43, and 178.6 mg of 1- (3-chlor
- Step 1 In a 250 mL tricolor, 1.2 g of ethyl 2-phenyl-1-H-pyrrol-3-yl-carboxylate, which can be prepared according to J. Chem. Soc. Perkin Trans I 1994 (17), 2355-56, in 80 mL of ethanol and 19.5 mL of 1N aqueous sodium hydroxide solution; then reflux for 48 hours. After concentrating the ethanol under reduced pressure, the reaction medium is dissolved in 25 ml of distilled water. The aqueous solution obtained is washed with 3 times 10 ml of ethyl acetate and then acidified by addition of 39.5 ml of a 1 N aqueous solution of hydrochloric acid.
- Step 2 The procedure is as in Example 5, but starting from 375 mg of 2-phenyl-1-H-pyrrol-3-yl-carboxylic acid, prepared above, and 440 mg of 1- ( 3,5-dimethoxy-phenyl) piperazine in 30 mL of dichloromethane, in the presence of 420 mg of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI) and 27 mg of 1-hydroxybenzotriazole hydrate (HOBT) stirring at room temperature for 72 hours, after 24 hours, 20 ml of dichloromethane were added.
- EDCI 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride
- HOBT 1-hydroxybenzotriazole hydrate
- Example 5 The procedure is as in Example 5, but starting from 189 mg of 4-phenyl-1-H-imidazol-5-yl-carboxylic acid, obtained in step 1 of Example 3, and 278 mg of 1- (3-carboxamido-phenyl) piperazine dihydrochloride, which can be prepared according to WO98 / 00400, in 35 ml of dichloromethane, in the presence of 422 ⁇ l of triethylamine, 211 mg of 1-chlorohydrate ( 3-dimethylaminopropyl) -3-ethylcarbodiimide (EDCI) and 148 mg of 1-hydroxybenzotriazole hydrate (HOBT), with stirring at room temperature for 20 hours. The precipitate obtained is drained, washed successively with
- Example 5 The procedure is as in Example 5, but starting from 195 mg of 2-phenyl-1H-pyrrol-3-yl-carboxylic acid, obtained in step 1 of Example 21, and 280 mg of 1- (3-carboxamido-phenyl) piperazine dihydrochloride, which may be prepared according to WO9800400, in 35 ml of dichloromethane, in the presence of 420 ⁇ l of triethylamine, 210 mg of 1- (3-dimethylaminopropyl) -3-hydrochloride ethylcarbodiimide (EDCI) and 150 mg of 1-hydroxybenzotriazole hydrate (HOBT), with stirring at room temperature for 20 hours.
- 1- (3-carboxamido-phenyl) piperazine dihydrochloride which may be prepared according to WO9800400, in 35 ml of dichloromethane, in the presence of 420 ⁇ l of triethylamine, 210 mg of 1- (3-dimethylaminopropy
- the precipitate obtained is drained, washed successively with 2 times 5 ml of dichloromethane, 2 times 20 ml of water, 2 times 20 ml of a saturated aqueous solution of sodium hydrogencarbonate and then twice with 20 ml of water.
- the precipitate is then purified by flash chromatography on silica gel (60, 30-75 ⁇ M) eluting with a mixture of dichloromethane and ethanol (90-10 by volume).
- Example 5 The procedure is as in Example 5, but starting from 189 mg of 2-phenyl-1H-pyrrol-3-yl-carboxylic acid, obtained in step 1 of Example 21, and of 200 mg of 1- (3-chloro-phenyl) piperazine in 15 mL of dichloromethane, in the presence of 210 mg of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI) and 13 mg of 1-hydroxybenzotriazole hydrate (HOBT), with stirring at room temperature for 72 hours.
- EDCI 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride
- HOBT 1-hydroxybenzotriazole hydrate
- the precipitate obtained is drained, washed successively with 2 times 5 ml of dichloromethane, 2 times 20 ml of water, 2 times 20 ml of a saturated aqueous solution of sodium hydrogencarbonate and then twice with 20 ml of water.
- the precipitate is then purified by flash chromatography on silica gel (60; 30-75 ⁇ M) eluting with a mixture of dichloromethane and ethanol (95-5 by volume).
- Example 5 The procedure is as in Example 5, but starting from 188 mg of 4-phenyl-1-H-imidazol-5-yl-carboxylic acid, obtained in step 1 of Example 3, and 192 mg of 1- (3-methoxy-phenyl) piperazine in 20 ml of dichloromethane, in the presence of 211 mg of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI) and 148 mg of hydrate of 1-hydroxybenzotriazole (HOBT), stirring at room temperature for 20 hours.
- EDCI 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride
- HOBT 1-hydroxybenzotriazole
- Step 1 Tert-butyl 4- (3-Difluoromethoxy-phenyl) -piperazin-1-yl-carboxylate
- the reaction mixture is diluted with water (20 ml) and then extracted with ethyl acetate (2 ⁇ 30 ml). The organic extracts are combined, dried over magnesium sulphate, filtered and evaporated under reduced pressure.
- the compound obtained is purified by chromatography on silica gel (AIT cartridge, Ref FC-25 Si-BP-SUP, 20-40 ⁇ m, dichloromethane eluent, flow rate of 20 ml / min). The fractions containing the expected compound are combined and then evaporated under reduced pressure.
- the expected tert-butyl 4- (3-difluoromethoxy-phenyl) -piperazin-1-yl-carboxylate (253 mg), which has the following characteristics, is isolated.
- Step 2 1- (3-Difluoromethoxy-phenyl) -piperazine Hydrochloride
- a solution of tert-butyl 4- (3-difluoromethoxyphenyl) -piperazin-1-carboxylate (253 mg, 3.8 mmol) in a mixture of dioxane (1016 ⁇ l) and hydrochloric acid (963 ⁇ l).
- the mixture reactionnei is stirred at 20 ° C for 48 hours.
- the solid formed is filtered off, washed (diisopropyl ether, 10 ml) and dried under reduced pressure.
- Step 3 The procedure is as in Example 5, but starting from 376 mg of 4-phenyl-1-H-imidazol-5-yl-carboxylic acid, obtained in step 1 of Example 3, and of 602 mg of 1- (3-difluoromethoxy-phenyl) -piperazine dihydrochloride in 50 ml of dichloromethane, in the presence of 0.618 ml of triethylamine, 422 mg of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride ( EDCI) and 296 mg of 1-hydroxybenzotriazole hydrate (HOBT), with stirring at room temperature for 20 hours.
- EDCI 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride
- HOBT 1-hydroxybenzotriazole hydrate
- MCPBA meta-chloro-perbenzoic acid
- Example 32 The procedure is as in Example 32, but the first fraction is collected. After acidification of this elution fraction with 132 ⁇ l of 1 M hydrochloric acid, 53 mg of 3- ⁇ 3- [4- (3-chlorophenyl) -piperazin-1-carbonyl] hydrochloride are collected. methyl phenyl-pyrrol-1-yl ⁇ propionate; as amorphous beige solid whose characteristics are as follows:
- Step 1 391.5 mg of [4- (3,5-dimethoxy-phenyl) -piperazin-1-yl] - (4-phenyl-1-H-pyrrol-3-yl) -methanone, prepared by stirring.
- Example 16 in 10 mL of pyridine. After cooling to 0 ° C., 90 mg of 60% sodium hydride in oil, previously washed by decantation in toluene, are added portionwise and the mixture is stirred at 0 ° C. for 30 minutes. 241 mg of (2-bromoethoxy) -tert-butyl dimethylsilane are then added and the mixture is heated at 60 ° C. for 3 hours and then stirred at room temperature for 20 hours.
- the pyridine is concentrated under reduced pressure and the residue is taken up in 50 ml of water and then extracted with 3 times 25 ml of ethyl acetate. After drying over magnesium sulphate and concentration under reduced pressure, purification is obtained by flash chromatography on silica gel (60, 30-75 ⁇ M), eluting with a mixture of dichloromethane and methanol (97.5-2.5 g).
- Step 1 In a 250 ml three-necked flask, a solution of 3.25 g of 1-boc-piperazine in 115 ml of toluene is placed, then 369.4 mg of (R) - (+) - 2,2 bis (diphenylphosphino) -1,1'-binaphthyl, 3.176 g of 3-bromobenzonitrile, 133.2 ml of palladium acetate and 2.516 g of sodium tert-butoxide. The reaction mixture is stirred and heated at 80 ° C for 16 hours and then diluted with 110 mL of water. The aqueous phase is decanted and then extracted with 120 mL of ethyl acetate.
- the organic extracts are combined, dried over magnesium sulphate, filtered and evaporated under reduced pressure.
- the compound obtained is purified by chromatography on silica gel (AIT cartridge, Ref FC-150-Si-BP-SUP, 20-40 ⁇ m, deposition solvent: dichloromethane, then cyclohexane elution / ethyl acetate 75/25 v v / v, flow rate of 20 mL / min until crystallization of the compound on the column).
- the silica column is flowed in 8 equal sections, the silica of each section being then extracted with ethyl acetate (20 ml) yielding different fractions.
- Step 2 In a 250 ml flask, place a solution of 3.81 g of tertobutyl 4- (3-cyano-phenyl) -piperazin-1-yl-carboxylate, obtained previously in 100 ml of methanol; then 24 ml of a molar solution of aqueous sodium hydroxide is added. The reaction mixture is refluxed for 36 hours and then evaporated under reduced pressure. The residue is taken up in 150 mL of ethyl acetate and 150 mL of water and decanted. The aqueous phase is extracted with 100 ml of ethyl acetate.
- Step 3 In a 100 mL flask, a solution of 2.01 g of tert-butyl 4- (3-carbamoyl-phenyl) -piperazin-1-yl-carboxylate in 8 mL of dioxane is placed; then 8 ml of a solution of 4M hydrochloric acid in dioxane is added and stirred at 20 ° C for 16 hours. The solid formed is filtered, washed with ethyl ether and dried under reduced pressure. In this way 1. 57 g of 3- (piperazin-1-yl) -benzamide are obtained, the characteristic of which is as follows:
- Step 4 In a 100 ml three-necked flask placed under argon, a mixture of 500 mg of 3-phenyl-1H-pyrrol-2-yl-carboxylic acid, obtained in step 1 of example 6, is placed. 563.2 mg of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI), 397 mg of 1-hydroxybenzotriazole (HOBT) and 710.2 mg of 3- (piperazin-1-yl) benzamide under stirring in 40 mL of dichloromethane; then 1, 24 ml of triethylamine is added.
- EDCI 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride
- HOBT 1-hydroxybenzotriazole
- 3- (piperazin-1-yl) benzamide under stirring in 40 mL of dichloromethane; then 1, 24 ml of triethylamine is added.
- the reaction mixture is stirred at 20 ° C for 16 hours and then diluted with 50 mL of dichloromethane and 50 mL of water. After decantation, the mixture is extracted with 20 ml of dichloromethane. The organic extracts are combined, dried over magnesium sulphate, filtered and evaporated under reduced pressure.
- the crude compound obtained is taken up in ethyl acetate (15 ml) and methanol (5 ml), dissolved and left at 20 ° C. for 48 hours. The solid formed is filtered, washed with ethyl acetate (5 mL) and then with ethyl ether and dried under reduced pressure.
- the reaction mixture is diluted with water (15 mL) and extracted with ethyl acetate (15 mL).
- the aqueous phase is extracted with ethyl acetate (2 ⁇ 10 mL).
- the organic extracts are combined, dried over magnesium sulphate, filtered and evaporated under reduced pressure.
- the compound obtained is purified by chromatography on silica gel (Cartridge 26 x 135, Ref 1511-1000, silica 10g, 15-40 ⁇ m, eluent cyclohexane / ethyl acetate, 9/1 v / v, flow rate of 10 mL / min).
- Step 2 To a solution of 200 mg of 2-amino-4-phenylthiazol-5-ylcarboxylic acid, and 202 mg of 1- ( 3,5-dimethoxy-phenyl) -piperazine in 25 ml of dichloromethane are added 192 mg of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI) and 135 mg of 1-hydroxybenzotriazole hydrate (HOBT). .
- EDCI 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride
- HOBT 1-hydroxybenzotriazole hydrate
- Step 1 To a solution of 3.5 g of ethyl 2-methyl-5-phenyl-1H-imidazol-4-yl-carboxylate, which can be obtained according to the patent application WO95 / 04724, in 30 mL distilled water and 60 ml of ethanol is added 1 g of potassium hydroxide pellets. After heating for 20 hours under reflux and then returning to ambient temperature, the reaction mixture is concentrated under reduced pressure, and the residue is acidified with 1N hydrochloric acid. Thus, after filtration of the solid formed, 3 g of 2-methyl-5-phenyl-1H-imidazol-4-yl-carboxylic acid, in the form of a beige solid, the characteristic of which is as follows:
- Step 2 To a solution of 140 mg of 2-methyl-5-phenyl-1H-imidazol-4-yl-carboxylic acid, in 15 mL of dichloromethane, 146 mg of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI),
- the pyridine is concentrated under reduced pressure and the residue is taken up in 50 ml of water and then extracted with 3 times 25 ml of ethyl acetate.
- the combined "dichloromethane" phases are concentrated to dryness under reduced pressure and the residue is purified by flash chromatography on silica gel (60, 30-75 microM) eluting with a mixture of dichloromethane and methanol (95-5 by volume) .
- Methyl 2- ⁇ 3- [4- (3,5-Dimethoxy-phenyl) -piperazin-1-yl] carbonyl-2-phenyl-1H-pyrrol-1-yl ⁇ -acetate 350 mg. - (3,5-dimethoxy-phenyl) -piperazin-1-yl] - (2-phenyl-1H-pyrrol-3-yl) -methanone, prepared in Example 8, in 15 mL of pyridine. After cooling to 0 ° C., 54 mg of 60% sodium hydride in oil, previously washed by decantation in toluene, are added portionwise, and the mixture is stirred at 0 ° C. for 30 minutes.
- Example 5 The procedure is as in Example 5, but on the one hand 430 mg of 1-methyl-2-phenyl-1-H-pyrrol-3-yl-carboxylic acid, which can be prepared as in step 1 of Example 21, and on the other hand 420 mg of 1- (3-carboxamido-phenyl) -piperazine dihydrochloride, which can be prepared according to WO98 / 00400, in 50 ml of dichloromethane, in the presence of 320 mg of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI), 20 mg of 1-hydroxybenzotriazole hydrate (HOBT) and 0.6 mL of triethylamine, with stirring at room temperature for 20 hours.
- EDCI 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride
- HOBT 1-hydroxybenzotriazole hydrate
- Step 1 391.5 mg of [4- (3,5-dimethoxy-phenyl) -piperazin-1-yl] - (2-phenyl-1-H-pyrrol-3-yl) -methanone, prepared by stirring.
- Example 8 in 20 mL of pyridine. After cooling to 0 ° C., 64.5 mg of 60% sodium hydride in oil, previously washed by decantation in toluene, are added portionwise, and the mixture is stirred at 0 ° C. for 30 minutes. 0.25 ml of (2-bromoethoxy) -tert-butyl dimethylsilane are then added and the mixture is stirred at room temperature for 20 hours.
- Step 2 To a solution of 550 mg of ⁇ 1- [2- (tert-butyl-dimethyl-silanyloxy) -ethyl] -2-phenyl-1H-pyrrol-3-yl ⁇ - [4- (3.5 g) (dimethoxy-phenyl) -piperazin-1-yl] -methanone in 20 ml of tetrahydrofuran are added 8 ml of a 1 M solution of tetra-N-butylammonium fluoride in tetrahydrofuran.
- Step 2 The procedure is as in Example 5, but on the one hand 120 mg of 2-trifluoromethyl-4-phenyl-1-H-imidazol-5-yl-carboxylic acid, and secondly 130 mg of 1- (3-carboxamido-phenyl) -piperazine dihydrochloride, which may be prepared according to WO98 / 00400, in 20 ml of dichloromethane, in the presence of 99 mg of 1- (3-dimethylaminopropyl) -3-hydrochloride ethylcarbodiimide (EDCI), 70 mg of 1-hydroxybenzotriazole hydrate (HOBT) and 0.20 ml of triethylamine, with stirring at room temperature for 20 hours.
- EDCI 1- (3-dimethylaminopropyl) -3-hydrochloride ethylcarbodiimide
- HOBT 1-hydroxybenzotriazole hydrate
- Example 55 The procedure is as in Example 55, but starting from 200 mg of 3- [4- (2-mercapto-4-phenyl-1H-imidazol-5-ylcarbonyl) -piperazin-1-yl] -benzonitrile obtained in Example 52, 33 mg of sodium methylate and 35 ⁇ l of methyl iodide in 20 ml of methanol. After recrystallization from diisopropyl ether, 106 mg of 3- [4- (2-methylsulfanyl-4-phenyl-1H-imidazol-5-ylcarbonyl) -piperazin-1-yl] benzonitrile, in the form of a white powder, the characteristic of which is as follows:
- Step 1 850 mg of 4-Fertbutylcarbonyloxy-1- (3-hydroxymethyl-phenyl) piperazine, which can be prepared according to WO00 / 15646, are dissolved in 40 ml of dioxane. 3.64 ml of a 4N solution of hydrochloric acid in dioxane are then added and the mixture is stirred for 1 hour at 0 ° C. The precipitate formed is drained, washed with diethyl ether and dried under reduced pressure. 770 mg of 1- (3-hydroxymethyl-phenyl) -piperazine dihydrochloride are thus obtained in the form of a yellow powder which is used as it is in the next step.
- Step 2 The procedure is as in Example 5, but starting from 145 mg of 2-hydroxy-4-phenyl-1-H-imidazol-5-yl-carboxylic acid, which can be prepared according to Heterocycles 1984, 22 (8), 1763-6998-108, and on the other hand
- Example 5 The procedure is as in Example 5, but starting from 1.404 g of 4-phenyl-1-H-pyrrol-3-yl-carboxylic acid, which can be prepared according to Med. Chem. Res. 1997, 7 (2), 98-108, and secondly 2.086 g of 1- (3-carboxamido-phenyl) -piperazine dihydrochloride, which can be prepared according to WO98 / 00400, in 100 ml of dichloromethane, in 1.
- Example 5 The procedure is as in Example 5, but starting with 200 mg of 2-trifluoromethyl-4-phenyl-1-H-imidazol-5-yl-carboxylic acid, prepared as in Step 1 of Example 54, and 174 mg of (3,5-dimethoxy-phenyl) -piperazine, in 30 ml of dichloromethane, in the presence of 165 mg of 1- (3-dimethylaminopropyl) hydrochloride. ethylcarbodiimide (EDCI) and 116 mg of 1-hydroxybenzotriazole hydrate (HOBT), with stirring at room temperature for 72 hours.
- EDCI ethylcarbodiimide
- HOBT 1-hydroxybenzotriazole hydrate
- Step 2 To a solution of 400 mg of 3- ⁇ 4- [1- (tert-butyl-dimethyl-silanyloxy) -ethyl-4-phenyl-1H-pyrrol-3-yl-carbonyl] -piperazine-1 4-Benzamide in 12 ml of tetrahydrofuran are added 6 ml of a 1 M solution of tetra-N-butylammonium fluoride in tetrahydrofuran. After stirring for 20 hours at 20 ° C., 50 ml of ethyl acetate are added, the mixture is washed with 3 times 25 ml of water, dried over magnesium sulphate and concentrated to dryness under reduced pressure.
- Step 1 13 g of ethyl 2-mercapto-4-phenyl-1H-imidazol-5-yl-carboxylate, which can be prepared according to Chem. Pharm. Bull. 1984, 32 (7), 2536-43, are dissolved in 500 mL of methanol. After cooling to 0 ° C., 3.4 g of sodium methylate are added portionwise and the mixture is stirred for 30 minutes while allowing to return to ambient temperature. It is cooled again to 0 ° C., a solution of 3.3 g of methyl iodide in 25 ml of methanol is added dropwise and the mixture is refluxed for 8 hours.
- Step 2 7 g of ethyl 2-methylsulfanyl-4-phenyl-1H-imidazol-5-yl-carboxylate are dissolved in 200 mL of methanol, then 24.6 g of oxone® - or potassium peroxomono sulfate (2KHSO 5. KHSO4, K 2 SO 4 ) - in solution in 100 mL of water. After stirring for 20 hours at room temperature, 200 ml of water are added and then the mixture is extracted three times with 100 mL of ethyl acetate. The combined organic phases are washed with water, washed with a saturated aqueous solution of sodium chloride, dried over magnesium sulfate and concentrated under reduced pressure.
- Step 4 The procedure is as in Example 5, but starting from 444 mg of 2-methylsulfonyl-4-phenyl-1H-imidazol-5-yl-carboxylic acid on the one hand and of 333 mg of (3,5-dimethoxy-phenyl) -piperazine in 37.5 mL of dichloromethane in the presence of 316 mg of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI) and 223 mg of hydrate
- Example 5 The procedure is as in Example 5, but starting on the one hand with 133 mg of 1-methyl-4-phenyl-1-H-pyrrol-3-yl-carboxylic acid, which can be prepared according to Med. Chem. Res. (1997), 7 (2), 98-108, and 175 mg of 1- (3-hydroxymethyl-phenyl) piperazine dihydrochloride, prepared as in step 1 of Example 57, in 25 ml of dichloromethane, in the presence of 139 mg of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI), 98 mg of 1-hydroxybenzotriazole hydrate (HOBT) and 204 ⁇ l of triethylamine, with stirring at room temperature for 20 minutes.
- EDCI 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride
- HOBT 1-hydroxybenzotriazole hydrate
- Example 5 The procedure is as in Example 5, but starting with 600 mg of 2-methylsulfonyl-4-phenyl-1H-imidazol-5-yl-carboxylic acid, prepared in step 3 of Example 67, and 528 mg of 1- (3-cyanophenyl) piperazine dihydrochloride, prepared according to Tetrahedron Lett. 2000, 56 (24), 4107-10, in 50 mL of dichloromethane, in the presence of 428 mg of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI), 301 mg of 1-hydroxybenzotriazole hydrate. (HOBT) and 627 ⁇ L of triethylamine, with stirring at room temperature for 20 hours.
- 1- (3-cyanophenyl) piperazine dihydrochloride prepared according to Tetrahedron Lett. 2000, 56 (24), 4107-10, in 50 mL of dichloromethane, in the presence of 428 mg of 1- (3-
- Example 5 The procedure is as in Example 5, but starting with 600 mg of 2-methylsulfonyl-4-phenyl-1H-imidazol-5-yl-carboxylic acid, prepared in step 3 of Example 67, and 564 mg of 1- (3-carboxamidophenyl) piperazine dihydrochloride in 68 mL of dichloromethane, in the presence of 428 mg. of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI), 301 mg of 1-hydroxybenzotriazole hydrate (HOBT) and 627 ⁇ l of triethylamine, with stirring at room temperature for 20 hours.
- EDCI 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride
- HOBT 1-hydroxybenzotriazole hydrate
- Step 1 A solution of 2.6 g of tert-butyl 4- (3-cyano-phenyl) -piperazin-1-yl-carboxylate (obtained as described in step 1 of Example 39) in dioxane (15 ml) a solution of 4M hydrochloric acid in dioxane (11.6 ml) is added and the reaction mixture is stirred at 20 ° C.
- Step 2 In a 100 ml three-necked flask placed under argon, a mixture of 300 mg of 3-phenyl-1H-pyrrol-2-yl-carboxylic acid, obtained in step 1 of example 6, is placed. 307 mg of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI), 216 mg of 1-hydroxybenzotriazole (HOBT) and 417.2 mg of 3- (piperazin-1-yl) -benzonitrile obtained from the previous step in 30 mL of dichloromethane; then 0.74 mL of triethylamine is added.
- EDCI 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride
- HOBT 1-hydroxybenzotriazole
- 3- (piperazin-1-yl) -benzonitrile obtained from the previous step in 30 mL of dichloromethane; then 0.74 mL of
- the reaction mixture is stirred at 20 ° C for 16 hours and then diluted with 50 mL of dichloromethane and 50 mL of water. After decantation, the mixture is extracted with 20 ml of dichloromethane. The organic extracts are combined, washed with a saturated solution of ammonium chloride (20 ml), dried over magnesium sulphate, filtered and evaporated under reduced pressure.
- the crude compound obtained is purified by chromatography on silica gel (Bondelut cartridge, Ref 15111.1000, 26 mm diameter, 20 g of silica 15-40 microns), eluting at a flow rate of 12 ml / min with a mixture of cyclohexane and cyclohexane.
- Step 3 Starting from 130.1 mg of 3- [4- (3-phenyl-1H-pyrrol-2-ylcarbonyl) -piperazin-1-yl] -benzonitrile obtained above, in solution in dimethylformamide (1.5 ml) then 13 mg of sodium hydride and 61.4 mg of methyl bromoacetate are added and allowed to react at 20 ° C for 1.5 hours. The reaction being incomplete, a portion of sodium hydride (14 mg) and methyl bromoacetate (43 ⁇ l) are added.
- reaction mixture is treated as follows: dilution with water (20 ml) and ethyl acetate (20 ml), decantation, extraction with ethyl acetate ( 2x15 ml). The organic extracts are combined, dried over magnesium sulphate and then evaporated under pressure scaled down.
- the compound obtained is purified by chromatography on silica gel (AIT cartridge, ref FC-25Si-HP), eluting with a mixture of dichloromethane and methanol, 90/10 vol / vol at a flow rate of 10 ml / min.
- Step 4 In a 50 ml flask containing 95 mg of methyl ⁇ 2- [4- (3-cyano-phenyl) -piperazin-1-yl-carbonyl] -3-phenyl-pyrrol-1-yl ⁇ -acetate obtained previously, a solution of 0.1 M sodium hydroxide solution (491 ⁇ l) and methanol (3 ml) is added. The reaction mixture is stirred under reflux for 48 hours. The reaction is not complete, we introduce an additional portion of sodium hydroxide (250 .mu.l) while maintaining the reflux overnight.
- reaction mixture is evaporated to dryness and then purified by reversed-phase high performance chromatography (injection volume 5 ml DMSO, Nucleodur column, C18 100-10, 250x40 mm, ref 762020, serial no. 3051181, lot 2023). using a water / acetonitrile gradient (containing 0.07% of trifluoroacetic acid, from 95/5 to 5/95 -proportions in volumes- in 52 minutes at a flow rate of 75 ml / min). The fractions containing the expected compound are combined and evaporated.
- Step 2 The procedure is as in Example 5, but starting from 202 mg of 2-methyl-4-phenyl-1H-imidazol-5-yl-carboxylic acid on the one hand and 265 on the other hand.
- EDCI 1- (3-dimethylaminopropyl) -3-hydrochloride ethylcarbodiimide
- HOBT 1-hydroxybenzotriazole hydrate
- Step 2 To a solution of 95 mg of 3- ⁇ 4- [1- (tert-butyl-dimethyl-silanyloxy) -ethyl-2-phenyl-1H-pyrrol-3-yl-carbonyl] -piperazin-1-yl ⁇ -benzamide.
- Example 5 The procedure is as in Example 5, but starting from 265 mg of 2-mercapto-4-phenyl-1H-imidazol-5-yl-carboxylic acid, obtained according to Chem. Pharm. Bull. 1984, 32 (7), 2536-43, and on the other hand 220 mg of (3-hydroxy-phenyl) -piperazine dihydrochloride, obtained as in step 1 of Example 57, in 25 ml of dichloromethane in the presence of 211 mg of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI), 148 mg of 1-hydroxybenzotriazole hydrate (HOBT) and 309 ⁇ l of triethylamine, with stirring at room temperature for 20 hours.
- EDCI 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride
- HOBT 1-hydroxybenzotriazole hydrate
- Example 5 The procedure is as in Example 5, but starting from 521 mg of 2-mercapto-4-phenyl-1H-imidazol-5-yl-carboxylic acid, obtained as in step 1 of Example 67, and on the other hand 530 mg of (3-hydroxy-phenyl) -piperazine dihydrochloride, obtained as in Step 1 of Example 57, in 50 ml of dichloromethane, in the presence of 422 mg of hydrochloride.
- EDCI 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide
- HOBT 1-hydroxybenzotriazole hydrate
- Example 5 The procedure is as in Example 5, but starting with 157 mg of 1-methyl-2-phenyl-1H-pyrrol-3-ylcarboxylic acid, which can be prepared according to Med. Chem. Res. (1997), 7 (2), 98-108, and on the other hand 227 mg of (3-hydroxy-phenyl) -piperazine dihydrochloride, obtained as in step 1 of Example 57, in 50 ml. of dichloromethane, in the presence of 165 mg of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI), 12 mg of 1-hydroxybenzotriazole hydrate (HOBT) and 240 ⁇ l of triethylamine, with stirring at room temperature.
- EDCI 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride
- HOBT 1-hydroxybenzotriazole hydrate
- Step 1 430 mg of 3- [4- (2-phenyl-1H-pyrrol-3-ylcarbonyl) piperazin-1-yl] benzonitrile, prepared in Example 74, are dissolved in 20 mL of anhydrous pyridine. After cooling to 0 ° C., 72 mg of 60% sodium hydride in oil, previously washed by decantation in toluene, are added portionwise, the mixture is stirred at 0 ° C. for 30 minutes. 0.28 ml of (2-bromoethoxy) -fetf-butyl-dimethylsilane are then added and the mixture is stirred at ambient temperature for 20 hours.
- Step 2 To a solution of 550 mg of 3- ⁇ 4- [1- (tert-butyl-dimethyl-silanyloxy) -ethyl-2-phenyl-1H-pyrrol-3-yl-carbonyl] -piperazin-1 yl ⁇ -benzonitrile in
- Example 5 The procedure is as in Example 5, but on the one hand 256 mg of 2-trifluoromethyl-4-phenyl-1-H-imidazol-4-yl-carboxylic acid, prepared as in step 1 of Example 54, and on the other hand 265 mg of 1- (3-hydroxymethyl-phenyl) -piperazine dihydrochloride, prepared as in Step 1 of Example 57, in 25 ml of dichloromethane, in the presence of 211 mg of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI), 148 mg of 1-hydroxybenzotriazole hydrate (HOBT) and 309 ⁇ l of triethylamine, with stirring at room temperature for 20 hours.
- EDCI 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride
- HOBT 1-hydroxybenzotriazole hydrate
- Example 5 The procedure is as in Example 5, but on the one hand 256 mg of 2-trifluoromethyl-4-phenyl-1-H-imidazol-4-yl-carboxylic acid, prepared as in step 1 of Example 54, and 260 mg of 1- (3-cyanomethyl-phenyl) -piperazine dihydrochloride, prepared according to Tetrahedron Lett. 2000, 56 (24), 4107-10, in the presence of 211 mg of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI), 149 mg of 1-hydroxybenzotriazole hydrate (HOBT) and 309 ⁇ L of triethylamine, with stirring at room temperature for 20 hours.
- EDCI 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride
- HOBT 1-hydroxybenzotriazole hydrate
- Example 5 The procedure is as in Example 5, but starting from 256 mg of 2-phenyl-1H-pyrrol-3-yl-carboxylic acid, prepared as in Step 2 of Example 21, and on the other hand 265 mg of 1- (3-hydroxymethyl-phenyl) -piperazine dihydrochloride, prepared as in step 1 of Example 57, in the presence of 211 mg of 1- (3-dimethylaminopropyl) hydrochloride. 3-ethylcarbodiimide (EDCI), 149 mg of 1-hydroxybenzotriazole hydrate (HOBT) and 309 ⁇ l of triethylamine, with stirring at room temperature for 20 hours.
- EDCI 3-ethylcarbodiimide
- HOBT 1-hydroxybenzotriazole hydrate
- Step 1 500 mg of 3- [4- (4-phenyl-1H-pyrrol-3-ylcarbonyl) piperazin-1-yl] benzonitrile, prepared as in Example 61, are dissolved in 15 ml of dimethylformamide (DMF) anhydrous. After cooling to 0 ° C., 62 mg of 60% sodium hydride in oil, previously washed by decantation in toluene, are added portionwise, the mixture is stirred at 0 ° C. for 30 minutes. 370 mg of (2-bromo-ethoxy) -fer-butyl-dimethyl-silane are then added and the mixture is stirred at room temperature for 20 hours.
- DMF dimethylformamide
- the reaction medium is taken up in 50 ml of water and then extracted with 3 times 25 ml of ethyl acetate. After drying over magnesium sulphate and concentration under reduced pressure, the residue is purified by flash chromatography on silica gel (60, 30-75 ⁇ M) eluting with ethyl acetate.
- silica gel 60, 30-75 ⁇ M
- Step 2 To a solution of 720 mg of 3- ⁇ 4- [1- (tert-butyl-dimethyl-silanyloxy) -ethyl-4-phenyl-1H-pyrrol-3-yl-carbonyl] -piperazin-1 yl ⁇ -benzonitrile in
- Step 1 Dissolve 240 mg of [4- (3-hydroxymethyl-phenyl) -piperazin-1-yl] - (2-phenyl-1H-pyrrol-3-yl] -methanone prepared as in Example 86 In 40 ml of anhydrous pyridine, after cooling to 0 ° C., 40 mg of 60% sodium hydride in oil, previously washed by decantation in toluene, are added portionwise, stirred at 0 ° C. for 30 minutes.
- Step 2 To a solution of 98 mg of [4- (3-hydroxymethyl-phenyl) -piperazin-1-yl] - (1 - (tert-butyl-dimethyl-silanyloxy) ethyl-2-phenyl-1H-pyrrol 5 mL of methanone in 5 mL of tetrahydrofuran are added 1, 5 mL of a 1M solution of tetra-N-butylammonium fluoride in tetrahydrofuran, and the mixture is stirred for 20 hours at 20 ° C.
- Step 2 The procedure is as in Example 5, but starting from 200 mg of 2- (2-methoxy-ethyl) amino-4-phenyl-thiazol-5-yl-carboxylic acid and on the other hand 160 mg of (3,5-dimethylphenyl) piperazine in 20 ml of dichloromethane, in the presence of 151 mg of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI) and 107 mg of 1-hydroxybenzotriazole hydrate (HOBT), with stirring at room temperature for 72 hours.
- EDCI 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride
- HOBT 1-hydroxybenzotriazole hydrate
- Example 90 and on the other hand 160 mg of (3,5-dimethoxy-phenyl) piperazine in 20 ml of dichloromethane, in the presence of 151 mg of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI) and 107 mg of 1-hydroxybenzotriazole hydrate (HOBT), with stirring at room temperature for 20 hours.
- EDCI 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride
- HOBT 1-hydroxybenzotriazole hydrate
- Step 1 750 mg of ethyl 2-hydroxy-4-phenyl-thiazol-5-yl-carboxylate, which can be obtained according to Acta Bote Pharmaceutica 1984, 41 (6), 633-40, are dissolved in 8 ml of Ethanol, then 7.5 mL of a 2.5 N aqueous solution of sodium hydroxide is added and refluxed for 15 minutes. After concentrating the ethanol under reduced pressure, 20 ml of water are added and the mixture is acidified to pH 1 by addition of a 1N aqueous solution of hydrochloric acid. The precipitate formed is drained, washed with water and with diisopropyl ether. There is thus obtained 0.6 g of 2-hydroxy-4-phenyl-thiazol-5-yl-carboxylic acid, in the form of a yellow solid, used as such in the next step, the characteristic of which is as follows:
- Step 2 The procedure is as in Example 5, but starting from 400 mg of 2-hydroxy-4-phenyl-thiazol-5-yl-carboxylic acid on the one hand, and of 402 mg of (3,5-dimethoxy-phenyl) -piperazine in 50 ml of dichloromethane in the presence of 381 mg of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI) and 269 mg of 1-hydroxybenzotriazole hydrate (HOBT), stirring at room temperature for 20 hours.
- EDCI 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride
- HOBT 1-hydroxybenzotriazole hydrate
- Example 5 The procedure is as in Example 5, but starting with 200 mg of 2-hydroxy-4-phenyl-thiazol-5-yl-carboxylic acid, obtained as in Step 1 of Example 95. and 251 mg of (3-carboxamido-phenyl) -piperazine dihydrochloride in 25 ml of dichloromethane, in the presence of 190 mg of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI), 134 mg of 1-hydroxybenzotriazole hydrate (HOBT) and 279 ⁇ l of triethylamine, with stirring at room temperature for 20 hours.
- EDCI 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride
- HOBT 1-hydroxybenzotriazole hydrate
- Example 5 The procedure is as in Example 5, but starting from 308 mg of 4-phenyl-thiazol-5-yl-carboxylic acid, which can be obtained according to Acta Bote Pharmaceutica 1984, 41 (6), 633 -40, and on the other hand 417 mg of (3-carboxamido-phenyl) -piperazine dihydrochloride in 37.5 ml of dichloromethane, in the presence of 316 mg of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI), 223 mg of 1-hydroxybenzotriazole hydrate (HOBT) and 464 ⁇ l of triethylamine, with stirring at room temperature for 20 hours.
- EDCI 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride
- HOBT 1-hydroxybenzotriazole hydrate
- Example 5 The procedure is as in Example 5, but starting on the one hand with 100 mg of 2- (2-methoxy-ethyl) amino-4-phenyl-thiazol-5-yl-carboxylic acid, obtained in step 1 of Example 90, and 93.5 mg of (3-cyano-phenyl) -piperazine dihydrochloride, which can be prepared according to Tetrahedron Lett.
- Tubulin is purified from porcine brains according to published methods (Shelanski et al., 1973, Proc Natl Acad Sci.USA, 70, 765-768, Weinberger et al., 1975, Proc Natl Acad Sci. USA, 72, 1858-1862). Briefly, the brains are crushed and centrifuged in extraction buffer. The tubulin contained in the supernatant of the extract undergoes two successive cycles of polymerization at 37 ° C. and depolymerization at 4 ° C., before being separated from the MAPs (Microtubule Associated Proteins) by chromatography on a phosphocellulose P11 column (Whatman). . The tubulin thus isolated is more than 95% pure.
- MAPs Microtubule Associated Proteins
- RB / 2 30% glycerol the composition of which is MES-NaOH [2- (N-morpholino) -ethanesulfonic acid] 50 mM, pH 6.8; MgCl 2 0.25 mM; 0.5 mM EGTA; glycerol 30% (v / v), GTP (guanosine-5'-triphosphate) 0.2 mM.
- tubulin is adjusted to a concentration of 10 ⁇ M (1 mg / ml) in 30% glycerol RB / 2 buffer to which 1 mM GTP and 6 mM MgCl 2 are added .
- the polymerization is triggered by an increase of the temperature of 6 ° C to 37 ° C in a vessel of 1 cm optical path, placed in a UVIKON 931 spectrophotometer (Kontron) equipped with a thermostatically controlled cell holder.
- the increase in the turbidity of the solution is monitored at 350 nm.
- IC 50 is defined as the concentration of product that inhibits the rate of polymerization by 50%.
- a product whose IC 50 is less than or equal to 25 ⁇ M is considered very active.
- a product according to the invention may be useful for inhibiting the proliferation of tumor cells in vitro.
- HCT116 cells The proliferation of HCT116 cells was evaluated by measuring [ 14 C] -thymidine incorporation as follows.
- HCT116 cells (from ATCC) are cultured in DMEM medium (Gibco) which contains 10% fetal calf serum and antibiotics (penicillin 1%, streptomycin 1%).
- DMEM medium Gibco
- antibiotics penicillin 1%, streptomycin 1%
- the cells are seeded in 96-well cytostar microplates (Amersham), at a rate of 5000 cells per well.
- [ 14 C] thymidine 0.1 ⁇ Ci / well
- Variable concentrations of products up to 10 ⁇ M are used; the DMSO (solvent used to solubilize the products) must not exceed 0.5% in the medium.
- IC 50 is defined as the concentration of product that decreases radioactivity by 50% compared to an untreated control. It is considered that a product whose Cl 50 is less than 10 ⁇ M is cytotoxic Biological results
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Furan Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0306719A FR2855825B1 (fr) | 2003-06-04 | 2003-06-04 | Produits aryl-heteroaromatiques, compositions les contenant et utilisation |
FR0404889 | 2004-05-06 | ||
PCT/FR2004/001379 WO2004108685A1 (fr) | 2003-06-04 | 2004-06-03 | Produits aryl-heteroaromatiques, compositions les contenant et utilisation |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1641765A1 true EP1641765A1 (fr) | 2006-04-05 |
Family
ID=33512659
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04767247A Withdrawn EP1641765A1 (fr) | 2003-06-04 | 2004-06-03 | Produits aryl-heteroaromatiques, compositions les contenant et utilisation |
Country Status (17)
Country | Link |
---|---|
US (1) | US20050014765A1 (fr) |
EP (1) | EP1641765A1 (fr) |
JP (1) | JP4805813B2 (fr) |
KR (1) | KR20060006850A (fr) |
AR (1) | AR044586A1 (fr) |
AU (1) | AU2004245269A1 (fr) |
BR (1) | BRPI0411001A (fr) |
CA (1) | CA2528093A1 (fr) |
CL (1) | CL2004001359A1 (fr) |
HK (1) | HK1093339A1 (fr) |
IL (1) | IL172222A0 (fr) |
MX (1) | MXPA05012929A (fr) |
PA (1) | PA8604401A1 (fr) |
PE (1) | PE20050226A1 (fr) |
TW (1) | TW200510344A (fr) |
UY (1) | UY28350A1 (fr) |
WO (1) | WO2004108685A1 (fr) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050119251A1 (en) * | 2001-12-21 | 2005-06-02 | Jian-Min Fu | Nicotinamide derivatives and their use as therapeutic agents |
BRPI0515483A (pt) | 2004-09-20 | 2008-07-22 | Xenon Pharmaceuticals Inc | derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase |
WO2006034440A2 (fr) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Derives heterocycliques et leur utilisation en tant qu'agents therapeutiques |
BRPI0515488A (pt) * | 2004-09-20 | 2008-07-29 | Xenon Pharmaceuticals Inc | derivados de heterocìclicos e seu uso como agentes terapêuticos |
MX2007003332A (es) * | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa. |
TW200626139A (en) * | 2004-09-20 | 2006-08-01 | Xenon Pharmaceuticals Inc | Heterocyclic derivatives and their use as therapeutic agents |
AR051294A1 (es) * | 2004-09-20 | 2007-01-03 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa |
WO2006034446A2 (fr) * | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Derives heterocycliques et leur utilisation comme agents therapeutiques |
TW200626572A (en) * | 2004-09-20 | 2006-08-01 | Xenon Pharmaceuticals Inc | Heterocyclic derivatives and their use as therapeutic agents |
EP1814551A2 (fr) * | 2004-09-20 | 2007-08-08 | Xenon Pharmaceuticals Inc. | Derives de pyridazine destines a l'inhibition du desaturase-coa-stearoyl de l'humain |
EP2540296A1 (fr) | 2005-06-03 | 2013-01-02 | Xenon Pharmaceuticals Inc. | Dérivés d'arminothiazole utilisés comme inhibiteurs de la stéaroyl-coa désaturase humaine |
TW200800946A (en) * | 2005-08-15 | 2008-01-01 | Astrazeneca Ab | Substituted piperazines as metabotropic glutamate receptor antagonists |
WO2007119833A1 (fr) * | 2006-04-14 | 2007-10-25 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique azoté |
DE102006027229A1 (de) * | 2006-06-09 | 2007-12-20 | Grünenthal GmbH | 1,3-Disubstituierte 4-Methyl-1H-pyrrol-2-carbonsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln |
WO2008089005A2 (fr) * | 2007-01-12 | 2008-07-24 | Takeda Pharmaceutical Company Limited | Inhibiteurs de rénine |
WO2009117444A1 (fr) * | 2008-03-17 | 2009-09-24 | Northeastern University | Inhibiteurs d'hydrolase d'amide d'acides gras et monoacylglycérol lipase pour la modulation de récepteurs de cannabinoïde |
TWI469979B (zh) | 2008-12-24 | 2015-01-21 | Bial Portela & Ca Sa | 脂肪酸醯胺水解酶(faah)抑制劑、以及其藥學組成物與用途 |
KR101297652B1 (ko) * | 2010-11-25 | 2013-08-19 | 한국과학기술연구원 | 항암활성을 지닌 카르보아졸계 화합물 |
CA2862276A1 (fr) * | 2012-01-25 | 2013-08-01 | Kabushiki Kaisha Yakult Honsha | Compose pyrrole |
EA029899B1 (ru) | 2012-06-04 | 2018-05-31 | Идорсиа Фармасьютиклз Лтд | Производные бензимидазол-пролина |
MX2015004638A (es) | 2012-10-10 | 2015-07-14 | Actelion Pharmaceuticals Ltd | Antagonistas de receptores de orexina los cuales son derivados de [orto bi-(hetero-) aril]-[2-meta bi-(hetero-) aril)-pirrolidin-1-il]-metanona. |
EP2970241A1 (fr) | 2013-03-12 | 2016-01-20 | Actelion Pharmaceuticals Ltd. | Dérivés d'amide d'azétidine en tant qu'antagonistes des récepteurs d'oréxine |
SI3077391T1 (sl) | 2013-12-04 | 2018-11-30 | Idorsia Pharmaceuticals Ltd | Uporaba benzimidazol-prolinskih derivatov |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX9707561A (es) * | 1995-04-07 | 1997-12-31 | Schering Corp | Compuestos de carbonil piperazinilo y piperidinilo. |
US5880128A (en) * | 1996-05-08 | 1999-03-09 | Schering Corporation | Carbonyl piperazinyl and piperidinyl compounds |
DE10035927A1 (de) * | 2000-07-21 | 2002-03-07 | Asta Medica Ag | Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel |
DE10035928A1 (de) * | 2000-07-21 | 2002-03-07 | Asta Medica Ag | Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel |
DE10035908A1 (de) * | 2000-07-21 | 2002-03-07 | Asta Medica Ag | Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel |
FR2815032B1 (fr) * | 2000-10-10 | 2003-08-08 | Pf Medicament | Nouveaux derives d'aminophenyle piperazine ou d'amino phenyle piperide inhibiteurs de proteines prenyl transferase ainsi que leurs preparations |
PL375527A1 (en) * | 2002-06-29 | 2005-11-28 | Zentaris Gmbh | Arylcarbonylpiperazines and heteroarylcarbonylpiperazines and the use thereof for treating benign and malignant tumour diseases |
AU2003287965A1 (en) * | 2002-10-24 | 2004-05-13 | Carex Sa | Modulation of peroxisome proliferator activated receptors activity |
GB0228417D0 (en) * | 2002-12-05 | 2003-01-08 | Cancer Rec Tech Ltd | Pyrazole compounds |
-
2004
- 2004-06-02 AR ARP040101890A patent/AR044586A1/es not_active Application Discontinuation
- 2004-06-02 PE PE2004000556A patent/PE20050226A1/es not_active Application Discontinuation
- 2004-06-03 US US10/859,740 patent/US20050014765A1/en not_active Abandoned
- 2004-06-03 CL CL200401359A patent/CL2004001359A1/es unknown
- 2004-06-03 WO PCT/FR2004/001379 patent/WO2004108685A1/fr active Application Filing
- 2004-06-03 AU AU2004245269A patent/AU2004245269A1/en not_active Abandoned
- 2004-06-03 KR KR1020057023192A patent/KR20060006850A/ko not_active Application Discontinuation
- 2004-06-03 TW TW093115885A patent/TW200510344A/zh unknown
- 2004-06-03 EP EP04767247A patent/EP1641765A1/fr not_active Withdrawn
- 2004-06-03 CA CA002528093A patent/CA2528093A1/fr not_active Abandoned
- 2004-06-03 BR BRPI0411001-3A patent/BRPI0411001A/pt not_active IP Right Cessation
- 2004-06-03 JP JP2006508355A patent/JP4805813B2/ja not_active Expired - Fee Related
- 2004-06-03 MX MXPA05012929A patent/MXPA05012929A/es active IP Right Grant
- 2004-06-04 PA PA20048604401A patent/PA8604401A1/es unknown
- 2004-06-04 UY UY28350A patent/UY28350A1/es unknown
-
2005
- 2005-11-28 IL IL172222A patent/IL172222A0/en unknown
-
2006
- 2006-12-28 HK HK06114181.4A patent/HK1093339A1/xx not_active IP Right Cessation
Non-Patent Citations (1)
Title |
---|
See references of WO2004108685A1 * |
Also Published As
Publication number | Publication date |
---|---|
TW200510344A (en) | 2005-03-16 |
IL172222A0 (en) | 2011-08-01 |
CA2528093A1 (fr) | 2004-12-16 |
US20050014765A1 (en) | 2005-01-20 |
KR20060006850A (ko) | 2006-01-19 |
UY28350A1 (es) | 2004-12-31 |
AR044586A1 (es) | 2005-09-21 |
HK1093339A1 (en) | 2007-03-02 |
AU2004245269A1 (en) | 2004-12-16 |
PE20050226A1 (es) | 2005-05-18 |
WO2004108685A1 (fr) | 2004-12-16 |
BRPI0411001A (pt) | 2006-07-04 |
CL2004001359A1 (es) | 2005-05-06 |
MXPA05012929A (es) | 2006-02-28 |
JP4805813B2 (ja) | 2011-11-02 |
PA8604401A1 (es) | 2004-12-16 |
JP2006526596A (ja) | 2006-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1641765A1 (fr) | Produits aryl-heteroaromatiques, compositions les contenant et utilisation | |
JP6861858B2 (ja) | Ssao阻害剤 | |
FR2857966A1 (fr) | Produits aryl-heteroaromatiques, compositions les contenant et utilisation | |
EP1492785B9 (fr) | Derives de 2-hydroxy-3-heteroarylindole comme inhibiteurs de gsk3 | |
JP2008517945A (ja) | C−fmsキナーゼのインヒビターとしての芳香族アミド | |
CN105339350B (zh) | 二氢吡啶酮mgat2抑制剂 | |
WO2009062371A1 (fr) | Dérivés de carbamate et utilisation en tant que médicament | |
EP1966173B1 (fr) | Derives heterocycliques, leur preparation et leur application en therapeutique. | |
CA2096475A1 (fr) | Derives du benzimidazole; leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
WO2004078732A1 (fr) | Produits n-aryl-heteroaromatiques, compositions les contenant et utilisation | |
KR900006742B1 (ko) | N-[(2-옥소피롤리딘-1-일)아세틸]피페라진 유도체 및 노인성 치매용 약제 | |
JP3548958B2 (ja) | ドーパミンd3及びd4受容体に対して選択的活性を有する新規のイソオキサゾリルアルキルピペラジン誘導体とその製造方法 | |
US20050130989A1 (en) | N-arylheteroaromatic products compositions containing them and use thereof | |
EP1966167B1 (fr) | Derives diaryltriazolmethylamine, leur preparation et leur application en therapeutique. | |
KR102537615B1 (ko) | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 | |
JP4422964B2 (ja) | 5員複素環誘導体、その製造法及びその医薬としての使用 | |
KR100248643B1 (ko) | 아릴 및 헤테로아릴 알콕시나프탈렌 유도체 | |
FR2855825A1 (fr) | Produits aryl-heteroaromatiques, compositions les contenant et utilisation | |
FR2758329A1 (fr) | Derives d'imidazole-4-butane boronique, leur preparation et leur utilisation en therapeutique | |
FR2911136A1 (fr) | Derives de n-(4-cyano-1h-pyrazol-3-yl)methylamine substitues leur preparation et leur application en therapeutique. | |
JP2002322163A (ja) | ピペラジン誘導体 | |
WO2003099812A1 (fr) | Derives de phenyl-furane ou de phenyl-thiophene, leur preparation et leur application a titre de medicament | |
KR101663662B1 (ko) | 대사성 글루타메이트 수용체 1에 활성을 지닌 신규 아릴 아이소옥사졸 유도체 | |
FR2921063A1 (fr) | Ligands des recepteurs cannabinoides | |
WO2009027601A2 (fr) | Dérivés de pyrazole 3,5-carboxylates, leur préparation et leur application en thérapeutique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20060104 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
DAX | Request for extension of the european patent (deleted) | ||
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: MAILLIET, PATRICK Inventor name: TIRABOSCHI, GILLES Inventor name: THOMPSON, FABIENNE Inventor name: LE BRUN, ALAIN |
|
17Q | First examination report despatched |
Effective date: 20060509 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20130103 |